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CRL: How effective are medium-term CBT interventions for Borderline 
Personality Disorder? 
Objective: This systematic review and meta-analysis of randomised controlled trials 
(RCTs) examined the efficacy of 3-9 month long CBT interventions on the treatment of 
Borderline Personality Disorder.  
Method: PubMed, APA PsychNet and Web of Science databases were searched and 
screened for suitable studies. Data on the included studies’ characteristics, BPD and 
risk outcomes was extracted. Standardised mean difference (SMD) summary statistics 
were calculated and meta-analysed for BPD outcomes. 
Results: Ten RCTs were identified with BPD outcomes. The SMD calculated was -
2.56, (95% Confidence Interval -3.86, -1.26). Eight studies reported risk related 
outcomes. Three of these reported significant reductions in risk outcomes in 
comparison to control groups. There was significant heterogeneity amongst the studies.  
Conclusion: Medium-term interventions appear to be effective in reducing BPD 
symptoms. Medium-term interventions appear less effective in reducing risk symptoms 
specifically. The results may reflect a difference in the target audience of medium-term 
interventions compared with traditional interventions. Further high quality RCTs are 
needed to allow further exploration and subgroup analysis.  
 Keywords: Borderline Personality Disorder, CBT. 
 
SIP: An Evaluation of the Current Screening Tools used in the Offender Personality 
Disorder (OPD) Pathway 
The Offender Personality Disorder (OPD) Pathway faces the difficult task of 
identifying individuals who are eligible for their service from the entire probation 
caseload. The OASys Personality Disorder Screen (OASys PD) is a national screening 
tool used by the pathway to help with this task. This paper describes a quantitative 
evaluation of the effectiveness of this tool for correctly identifying eligible individuals 
for the OPD service in the South of England. The service uses an additional screening 
method involving specialist clinicians interviewing probation officers about individuals 
on their caseload. A qualitative analysis of clinician’s experience of this screening 





made for using the most time-effective and clinically-effective screening process. 
Continued use of the combination of the screening tool and the interviews is 
recommended with minor adjustments.  
Keywords: OASYs, Personality Disorder, Screening, Probation, Offender 
Personality Disorder Pathway 
 
MRP: Mental Defeat in Long Term Health Conditions 
Objectives: This study aimed to explore whether mental defeat (MD) occurs in long 
term health conditions (LTCs) and if it does, whether it differs across conditions with 
differing symptomology.  
Design: This study used a cross sectional questionnaire design with two groups; 
Inflammatory Arthritis (IA) and Chronic Kidney Disease (CKD).  
Methods: Participants in both groups completed a battery of questionnaires about their 
experience of, and their beliefs and feelings about their health condition. A mixed 
model ANOVA and stepwise regressions were conducted to explore associations.  
Results: A mixed model ANOVA revealed no significant differences in levels of MD 
between the two groups. However, both groups reported higher levels of MD than 
healthy controls. A stepwise regression revealed that MD, health anxiety, disability and 
catastrophizing were all associated with psychological distress. A second regression 
revealed that MD, age, and health anxiety predict fear of disease progression. 
Conclusion: Mental defeat occurred in both LTCs in this study and there was no 
difference between the two conditions. Mental defeat was associated with 
psychological distress and fear of disease progression.  
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This journal was picked due to its high impact factor and publication of similar 






Objective: This systematic review and meta-analysis of randomised controlled 
trials (RCTs) examined the efficacy of 3-9 month long CBT interventions on the 
treatment of Borderline Personality Disorder.  
Method: PubMed, APA PsychNet and Web of Science databases were searched 
and screened for suitable studies. Data on the included studies’ characteristics, BPD 
and risk outcomes was extracted. Standardised mean difference (SMD) summary 
statistics were calculated and meta-analysed for BPD outcomes. 
Results: Ten RCTs were identified with BPD outcomes. The SMD calculated 
was -2.56, (95% Confidence Interval -3.86, -1.26). Eight studies reported risk related 
outcomes. Three of these reported significant reductions in risk outcomes in 
comparison to control groups. There was significant heterogeneity amongst the studies.  
Conclusion: Medium-term interventions appear to be effective in reducing BPD 
symptoms. Medium-term interventions appear less effective in reducing risk symptoms 
specifically. The results may reflect a difference in the target audience of medium-term 
interventions compared with traditional interventions. Further high quality RCTs are 
needed to allow further exploration and subgroup analysis.  



















How effective are medium-term Cognitive Behavioural Therapy based interventions for 
Borderline Personality Disorder? 
 
To meet diagnostic criteria for Borderline Personality Disorder (BPD) in the DSM-V 
an individual “must show a pervasive pattern of instability of interpersonal 
relationships, self-image and mood, along with marked impulsivity, that begins by 
early adulthood and is present in a variety of contexts (American Psychiatric 
Association, 2013, p. 663). The UK prevalence of BPD is 0.4% for adults aged 16 and 
over with a greater prevalence in the younger adult female population; 1.4% of 16-34 
year old woman compared to 0.3% of men (Macmanus, Meltzer, Brugha, Bebbington, 
& Jenkins, 2009). 
 There is much debate over the use of the diagnostic construct of personality 
disorder due to stigma, labelling and negative associations that are made between these 
individuals and certain challenging behaviours such as self-harm (Gunderson, 2001). 
There is a clear consensus among health care professionals that the individuals 
described above often engage in risk-taking behaviour and therefore need high levels of 
support and effective treatment that can be associated with extensive use of services 
and resources (Bender et al., 2001). Of those diagnosed with BPD 69-80% engage in 
suicidal behaviour (Soloff, A., Kelly, Cornelius, & Ulrich, 1994) and the suicide rates 
for this patient group is 9% (Linehan, Rizvi, Welch, & Page, 2008). 
 Great advances have been made in the treatment of BPD following the 
development of group and individual interventions from different theoretical schools 
e.g. Dialectical Behaviour Therapy (DBT), Schema therapy and Mentalisation-based 
treatment (MBT). DBT, Schema Therapy and MBT have all been shown to be effective 
treatments and beneficial in reducing core BPD pathology (Giesen-Bloo, van Dyck, 
Spinhoven, & et al., 2006; Stoffers et al., 2012). This review will focus on interventions 
which have evolved from CBT as it was deemed above the scope of this review to 
compare therapies from all theoretical backgrounds.  
The biosocial theory of BPD suggests that individuals develop unhelpful ways 
of coping with extreme emotions due to a combination of biological predisposition and 
an invalidating environment when growing up (Linehan, 1993). Although the 
interventions in this review are varied, in line with this theory, they are all assumed to 
act on the same underlying processes e.g. give individuals the skills/knowledge to 





Although ‘traditional’ interventions such as DBT are effective in improving 
functioning in individuals with symptoms indicative of BPD (Wilks, Korslund, Harned, 
& Linehan, 2016) they are often lengthy and expensive e.g. DBT involves one group 
and one individual session per week and typically lasts 1-2 years. In the current climate 
resources are short and services need to consider whether individuals can be helped 
effectively with less input to meet the increasing demand for the NHS to provide more 
for less (Appleby, Galea, & Murray, 2014).  A recent review of the characteristics of 
patients entering into IAPT services found 16% met criteria for borderline personality 
disorder and 69% were at high-risk of personality disorder (Hepgul et al., 2016). With 
increasing numbers of individuals coming into services with difficulties in emotion 
regulation, relationships and self-harming behaviour, services are struggling to provide 
the long-term interventions.  
NICE (2009) guidelines recommend psychological therapy as a first-line 
treatment for individuals with characteristics of BPD however specifically advise 
against the use of brief psychological interventions (less than 3 months). In response to 
the increasing demand a number of medium-term interventions have been developed 
e.g. Systems Training for Emotional Predictability and Problem Solving (STEPPS), 
brief schema-therapy, short-term DBT and problem-solving therapy are all between 20 
weeks and 6 months in duration. There is some evidence for the efficacy of each of 
these therapies individually.  A meta-analysis of three randomised controlled trials 
(RCTs) and four longitudinal STEPPS studies concluded that the programme 
effectively reduced self-harming and improved social functioning (Somma et al., 2014). 
However, there is yet to be a synthesis of the highest quality research (RCTs) on 
whether medium-term interventions as a whole are effective in treating symptoms of 
BPD. A review which addressed whether current UK guidelines for BPD treatment are 
justified indicated that further research was needed to examine the efficacy of 
interventions of a shorter duration than the traditional one year plus (Omar, Tejerina-
Arreal, & Crawford, 2014). The increased use of briefer interventions, and an ever-
growing need for these, make a review of medium-term interventions timely.  
The literature uses the terms short-term, medium-term and longer-term 
interchangeably. For clarity in this review ‘short-term’ is defined as interventions of 
less than 3 months, ‘medium-term’ is anything from 3 months to 9 months and long 






Aims of the Study 
The aim of this systematic review was to identify and review available 
published evidence on medium-term CBT interventions for BPD, and to draw 
conclusions where possible on their efficacy.    
Methods 
Search Strategy 
Web of Science, APA PsychNet and PubMed were searched for articles written 
from 1980 onwards (to coincide with the DSM-II BPD diagnosis). Search terms were 
grouped under two headings ‘Diagnosis’ and ‘Intervention’. Diagnosis search terms 
included “borderline personality disorder”, “BPD”, “emotional instability”, “EID” and 
“complex trauma”. Intervention search terms included “behaviour therapy”, “behavior 
therapy”, “cognitive behav*”, “CBT”, “STEPPS”, “schema” and “CAT”. Reference 
lists of included papers were also screened.  
 
Selection of the literature 
 Papers were imported into Endnote and duplicates were removed. Titles and 
abstracts were then reviewed to determine selection for full-text reading. Full texts of 
selected articles were studied to decide upon eligibility for inclusion. 
 The PICO framework used in this review for defining the (P)opulation, 
(I)ntervention, (C)comparison and (O)utcome of interest was as follows: 
 
• P: individuals diagnosed with BPD using a diagnostic tool which confirms DSM 
criteria  
• I: Interventions intended or designed to treat BPD that were underpinned by CBT 
and between 3 and 9 months in length and any modality (including CBT, DBT, 
STEPPS, Schema Therapy, Cognitive Analytic Therapy [CAT] and Acceptance 
and Commitment Therapy [ACT]) 
• C: studies with a control group (randomised)  
• O: a self-report or clinician administered outcome measure of BPD symptoms 





Studies were included if participates were 18 years or over, had a confirmed 
diagnosis of BPD, used any of the following outpatient based interventions; CBT, 
DBT, STEPPS, Schema Therapy, CAT or ACT in any modality. Only randomised 
controlled trials where there was an outcome measure of BPD symptoms pre-and post-
intervention were included.  
Studies were excluded if the complete intervention was less than 3 months or 
more than 9 months in duration or was started/completed/partially completed in an 
inpatient setting. Single case studies, reviews, books, conference abstracts and papers 
written in languages other than English were excluded. When it became clear that there 
were sufficient RCTs for a systematic review and meta-analysis, all those non-
randomised control group studies were excluded. RCTs which included long term 
interventions (9+ months) with outcomes taken at early time points (e.g. 6 months) 
were excluded as these interventions were deemed fundamentally different to 
interventions completed within the time-frame.  
 
Inter-rater Reliability 
A second rater screened 10% of the studies. The inter-rater agreement was 
initially 92%, with 100% agreement reached following discussion. A third rater was 
available to resolve any disagreement but was not needed.  
 
Data and Analysis 
Data on included studies’ characteristics and outcomes were extracted to be 
used in the review. This included the means (M) and standard deviations (SDs) both 
pre and post intervention for outcomes measuring BPD symptoms. Change scores for 
the mean difference were calculated (post-intervention minus pre-intervention) and the 
SD of the change were imputed for each study. To impute the SD of the change an 
estimated correlation coefficient (corr) was required in the equation. A corr value of 
0.99 was used. This value of corr was calculated from original data from one included 
study (Blum et al., 2008) and used as an estimate. This was the only study where 
enough information was reported to calculate the corr value and it is recommended that 
corr be imputed from another study in the meta-analysis, or estimated, when not 





 A meta-analysis of the change from baseline scores was completed using the 
standardised mean difference (SMD) as a summary statistic because the studies used 
different outcome measures of BPD symptoms. A random-effects model was used as 
this is most appropriate when studies involved in a meta-analysis are assumed to have 
high heterogeneity in samples, interventions and conditions.  The heterogeneity 
amongst the studies was assessed using the Cochran’s Q test.  
As the estimated corr was very high, a sensitivity analysis (meta-analysis) was 
completed using effect sizes calculated with an estimated corr value of 0.7. This 
involved running the meta-analysis again with change scores calculated using corr = 
0.7 to check whether or not the results changed qualitatively and therefore were reliant 
on the estimated value or not.  
 
Risk of Bias Assessment  
To assess for risk of bias the Cochrane Collaboration’s Tool (J. P. T. Higgins, 
Altman, & Sterne, 2011) was used. The tool is specifically designed for RCTs and 
assesses the risk of bias as a result of the methodology used. The tool focuses on 
selection bias (sequence generation, concealment of allocation), attrition bias, 
performance bias (participant and personnel blinding), detection bias (outcome 
assessment blinding) and reporting bias.  
The review followed the Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA; Moher, Liberati, Tetzlaff, & Altman, 2009). 
Results 
The initial search returned 3599 titles and abstracts. Duplicates were deleted and 2603 
abstracts were then screened by the lead researcher. Of these, 240 papers were selected 
for full-text assessment. After careful reading 230 papers were excluded for the 
following reasons; not original research, wrong study setting, wrong intervention 
length, wrong intervention type, non-English language and wrong participant group. 
Hence, 10 studies were included in the review (Figure 1).  No additional studies that 















Figure 1. Flowchart for inclusion of eligible studies  
 
 
230 papers excluded for the 
following reasons: 
not in English language 
wrong intervention length 
wrong not original research 
wrong study setting 
wrong intervention type 
wrong participant group 
 
Studies identified through database 
searching (n = 3599) 
Duplicates deleted (n = 996) 
Titles and abstracts screened (n = 
2603) 
Studies screened in full (n= 240) 
Studies to be included (n = 10) 











Risk of Bias 
Based on the Cochrane Risk of Bias Tool (Higgins et al., 2011) three studies 
were assessed as fair quality in relation to risk of bias overall and seven were assessed 
as poor (Table 1). Many of the risk of bias items were assessed as unclear due to 
insufficient information being reported. Across the studies, risk of bias was deemed 
high for reporting bias and allocation concealment. Items where risk of bias was 
deemed low across the majority of the studies were sequence generation and attrition 
bias. Both performance bias and detection bias ratings were mixed across the RCTs. 
The three RCTs rated as fair quality were all DBT intervention studies 
 
Study Characteristics 
 Table 2 summarises the included study’s characteristics. A total of 636 
participants took part in the 10 studies, published between 2001 and 2017. Participant 
numbers ranged from 20 to 124. Of the 10 papers, four were conducted in America, 
two in Spain and one in each of following countries; Denmark, Canada, Australia and 
the Netherlands.  
Diagnosis  
The studies used the following tools to confirm the DSM diagnosis of BPD; the 
Diagnostic Interview for Personality Disorders Revised (DIP-R; Zanarini, Frankenburg, 
Chauncey, & Gunderson, 1987); the Diagnostic Interview for Borderlines Revised 
(DIB-R; Zanarini, Gunderson, Frankenburg, & Chauncey, 1989); Borderline Syndrome 
Index (BSI; Conte, Plutchik, Karasu, & Jerret, 1980) and the Structured Clinical 
Interview for DSM-IV Axis II Disorders (SCID-II; First, Spitzer, Gibbon, & Williams, 
1995).  
Intervention Type and Control Groups 
Four of the studies used DBT as the intervention and two used STEPPS. One 
study used each of the following interventions: ACT, Cognitive Rehabilitation (CR), 
















studies used control conditions that were either treatment as usual (TAU) and/or 
waitlist (WL) whilst two used psychoeducation and standard group therapy (or a 
psychodynamic orientation) respectively. 
Intervention Format and Length  
All of the interventions included a group component. Seven studies solely used 
a group intervention whilst three used group plus individual sessions or telephone 
support. The interventions lasted between 13 weeks and 30 weeks with a mean length 
of 18.3 weeks. The Dutch version of STEPPS was 18 weeks long whereas the study 
conducted in America used the standard intervention length of 20 weeks. 
 
Study Outcomes 
BPD Symptoms Outcomes  
In total there were eight different measures of BPD symptoms used across the 
RCTs (Table 3). Nine studies used one measure of BPD symptoms and one study chose 
to use two.  
Four studies used clinician administered scales: The Zanarini Rating Scale for 
Borderline Personality Disorder (ZAN-BPD; Zanarini et al., 2003), the DIB-R 
(Zanarini et al., 1989), the Clinical Global Impression- Borderline Personality Disorder 
(CGI-BPD) and the SCID-II (First et al., 1995). Four studies used self-report measures; 
The Borderline Evaluation of Severity over Time (BEST), the Borderline Symptom 
List 23 (BSL-23), a short version of the BSL (Bohus et al., 2007), the BSI (Conte et al., 
1980) and the Borderline Personality Disorder Checklist- 40 (BPD-40) also known as 
the Borderline Personality Disorder Severity Index-IV(J. H. Giesen-Bloo, Wachters, 
Schouten, & Arntz, 2010). 
Meta-Analysis Results 
A meta-analysis on the effectiveness of the CBT interventions used in the 10 
studies on BPD symptoms was conducted. For the study where two outcome measures 
of BPD were reported (Farrell et al., 2009) the self-report measure, as opposed to the 
diagnostic measure, was used in the analysis. The results of the meta-analysis found a 
large negative effect size, d= -2.56 (95% CI -3.86; -1.26; Figure 2). That is to say that 
the interventions were effective in reducing BPD symptoms (scores on outcome 







BPD Outcome measures, means and standard deviations pre-and post- intervention for 





Pre M(SD) Post M(SD) Pre M(SD) Post M(SD) 
Andreasson 
et al. (2016) 
Zan-
BPD 
10 (6.5) 7.6 (18.12) 9.5 (5.4) 7.4 (9.29) 




18.9 (6.8) 9.8 (8.06) 17.3 (7.0) 13.4 (7.68) 






79.7 (25.8) 101.1 (33.3) 95.1 (29.1) 












32.75 (5.9);  
8.58 (1.51) 




25.83 (5.72) 37.30 (11.91) 34.7 (10.81) 

























42.32 (3.9) 42.56 (5.0) 40.42 (4.14) 38.89 (4.86) 




4.78 (0.8) 3.50 (1.2) 4.89 (0.33) 4.44 (0.52) 
Zan-BPD = Zanarini Rating Scale, BPD-40 = Borderline Personality Disorder 
Checklist- 40, BSI = Borderline Syndrome Index, DIB-R = Diagnostic Interview for 
BPD Revised, BEST = Borderline Evaluation of Severity over Time, SCID-II = 
Structured Clinical Interview for DSM-IV Axis II Disorders, BSL-23 = Borderline 
Symptom Checklist, CGI-BPD = Clinical Global Impression- Borderline Personality 








Figure 2. Meta-analysis using Standardised Mean Difference 
 
 
Figure 3. Funnel Plot of each studies’ standardised effect size against standard error 
There was significant heterogeneity amongst the 10 included studies and the Q 
test results were significant; Q(9) = 371.14, p< 0.001.  The SMD effect size was plotted 





asymmetrical with many points falling outside the inverted funnel, where 95% of 
studies are expected to fall if both publication bias and heterogeneity are not present. 
Whilst the heterogeneity of studies is likely to have contributed to this asymmetry, 
chance and reporting bias may also have contributed (Sterne et al., 2011).   
Sensitivity Analysis.  
 The results of the sensitivity analysis (completed using estimated corr = 0.7) 
did not differ qualitatively; there was still a large negative effect size d= -0.77 (95% CI 
-1.77; -0.37). This means that the results of the meta-analysis do not rest too heavily on 
the imputed value of corr (0.99) and the qualitative result can be taken with more 
reassurance.  
Narrative Review of BPD Outcomes  
Six of the studies reported statistically significant between group differences in 
favour of the intervention for BPD symptom outcomes. The interventions used in these 
studies were STEPPS, ERGT, ACT, DBT and Schema Focused Therapy. The largest 
effect size was found for Schema Focused Therapy. The intervention length in these 
studies varied from 12 weeks to 30 weeks.  
Four of the studies found no significant difference between the intervention and 
the control group for BPD symptom outcomes. Three of these studies used DBT 
interventions and the fourth used CR. The intervention length in these studies varied 
from 13 weeks to 26 weeks.  
Risk Outcomes 
 Eight of the ten studies included one or more outcome measure of risk 
symptoms. Three studies reported outcomes of risk of either incidence (%) or 
frequency (n) of self-harm or suicide attempts, four studies used outcome measures 
relating to self-harm and suicidality (Deliberate Self-Harm Inventory; DSHI, 
parasuicidal subscale of the BPDSI-IV, Beck Suicide Ideation Scale; BSIS) and two 
studies measure hopelessness (Beck Hopelessness Scale; BHS). Of the eight RCTs that 
measured risk only three of them reported a statistically significant difference in 
reduction of risk behaviours in the intervention group compared to the control group 
(see table 4 for a summary of the risk related outcome measures used by the different 
studies and where significant differences were found). Authors of three of the studies 





intervention (i.e. more than a single mode of DBT) may be needed to see an effect on 
risk behaviours. One study explained their neutral results as a consequence of the study 
being underpowered and the DBT delivery being poorer than in other trials. The three 
interventions which produced significant reductions in risk were ACT (Moreton et al., 
2012), ERGT (Gratz & Gunderson, 2006) and DBT (Koons et al., 2001). There were 
not clear differences between these studies and the others in terms of length, type or 
format of the interventions. The lengths were 12, 14 and 26 weeks; two were solely 
group interventions and one used group plus individual sessions. 
 See Table 5 for a summary of each studies’ quality rating and outcomes.  
 
Table 4 
Outcome measures used to assess risk and associated significance levels for each study 
Author (Year) Risk Outcomes Used Significant between 
group difference found?  
Andreasson et al. 
(2016) 
New self-harm in the group (%) 





Blum et al. (2008) Frequency of deliberate self-harm and suicide 
attempts (%) 
No 
Bos et al. (2010) % of the group > the cut-off on the impulsivity 
and Parasuicidal subscales of the BPDSI-IV 
No 
Gratz et al. (2006) Frequency of self-harm as measured by the 
DSHI 
Yes (<0.05) 
Koons et al. (2001) BSIS 
BHS 




Moreton et al. 
(2012) 
BHS Yes (p<0.05) 
McMain et al. 
(2017) 
Frequency of self-harm/suicide attempts from 
Lifetime Suicidal Attempt Interview and DSHI 
 
Greater reduction in 
DBT, approached but 
didn’t reach significance  
Soler et al. (2009) Rated self-injury and suicide attempts No  
BSIS = Beck Suicide Ideation Scale, BHS = Beck Hopelessness Scale, DSHI= Deliberate Self-






Summary Table for included RCTs  
Author Name 
(Year) 
Significant result for 
BPD Outcome? 
Significant result for 
Risk Outcome? Quality Rating 
Andreasson et al. 
(2016) 
No No Fair 
Blum et al. 
(2008) 
Yes No Poor 
Bos et al.    
(2010) 
Yes No Poor 
Farrell et al. 
(2009) 
Yes No Poor 
Gratz et al. 
(2006) 
Yes Yes Poor 
Koons et al. 
(2001) 
No Yes Poor 
Moreton et al. 
(2012) 
Yes Yes Poor 
McMain et al. 
(2017) 
Yes Nos Fair 
Pascual et al. 
(2015) 
No No Poor 
Soler et al. 
(2009) 
No No Fair 
 
Follow up 
 Six of the ten studies included a follow-up period. Two studies had a follow-up 
period of 3 months (McMain et al., 2017; Moreton et al., 2012), three studies had a 
follow-up period of 6 months (Bos et al., 2010; Farrell et al., 2009; Pascual et al., 2015) 
and one had a follow-up period of one year (Blum et al., 2008) All 
differences/improvements observed post-intervention were maintained or strengthened 
at follow-up in four studies, and the majority of improvements were maintained in the 
other cases. McMain et al. (2017) report that reductions in self-harm frequency, as 
measured by the LSASI, did not reach statistical significance post-intervention. 
However, by follow-up (12 weeks later) this difference was statistically significant 
(p<0.05) in comparison to the control group.   
Other Outcomes 
In addition to the primary outcome measures of this review (BPD symptoms 
and risk), the studies reported a variety of outcomes reflective of the variety of 





(Hasler, Hopwood, Jacob, Brandle, & Schulte-Vels, 2014). Outcome measures 
included psychological distress, risk, mood, functioning, quality of life and emotion 
regulation. It was deemed above the scope of this review to include all of these 
outcomes in analysis; however, additional outcome measure used by each study are 
provided for information in Appendix A 
Discussion 
 
Summary of Results 
This review summarised 10 RCTs on medium-term CBT interventions. A meta-
analysis found a large effect for the efficacy of the interventions on the treatment of 
BPD symptoms. There was significant heterogeneity amongst the included studies 
which was expected due to the variety of types of CBT interventions, lengths of 
interventions, outcome measures and participants used. The asymmetry displayed on 
the funnel plot suggests that the effect calculated in the meta-analysis may be an 
overestimation of the true intervention effects. Indeed, meta-analyses where there are a 
small number of studies and significant heterogeneity are prone to false-positive 
findings, therefore the results described here may need to be taken with caution 
(Higgins & Thompson, 2004).  
Of the eight RCTs which specifically measured risk outcomes, only three 
reported significant difference between the intervention and the control groups. The 
studies where this difference occurred had small sample sizes compared to the other 
studies in the review. The results suggest that medium term interventions are not 
consistently effective in reducing risk. One explanation for this may be that medium-
term interventions are not as focussed on risk reduction as their long-term counterparts. 
For example, studies were less likely to use specific risk measures indicating more of a 
focus on BPD symptom reduction. In contrast, long term interventions’ primary 
outcome measures relate to risk (e.g. reduction in self-harm or suicidal behaviours). It 
may be that longer and/or more intensive interventions are required to effectively 
reduce risk behaviours as suggested by authors of the studies. Longer term treatments 
have been shown in the literature to be effective in reducing suicidal and self-injurious 






One study exploring the different active components of DBT for high risk 
individuals compared group, individual and combined modalities. Authors concluded 
that combined (standard) DBT is superior for some cases and that interventions 
including the group skills component are more effective than those without (Linehan et 
al., 2015). The results of this review do not fit with this pattern (multiple components 
of DBT, including skills, did not result in superior outcomes), further highlighting the 
differences between long-term and medium-term DBT.  
 
Strengths and Limitations of this review 
 A strength of this review is that it is the first review to specifically include only 
RCTs of medium-term interventions, an important area clinically as demands on 
service’s resources and time increases. The broad intervention category (CBT-based 
approaches as opposed to only including traditional CBT interventions) will have 
contributed to the high heterogeneity amongst studies however this reflects the nature 
of the variety of interventions on offer for individuals with BPD, making the results 
more applicable for clinicians. A further strength of this review is the meta-analysis 
method used. Using change scores instead of final scores in the analysis means 
differences between the groups at baseline are controlled for. In addition, the sensitivity 
analysis results are reassuring that assumptions made when imputing scores were 
appropriate.  
Limitations of this review include the relatively small number of RCTs 
included. This meant that subgroup analysis was not possible, despite the overall meta-
analysis result suggesting significant heterogeneity amongst the studies. A further 
limitation is the lack of inter-rating for the risk of bias and the data extraction for the 
meta-analysis, making both of these areas more open to error. Evidence based 
interventions that are not CBT based, e.g. MBT, were also missed by this meta-
analysis.  
This review used the Cochrane risk of bias tool which is deemed gold-standard 
to use in reviews of RCTs. However, the tool was initially designed for drug-controlled 
trials and therefore the applicability and usefulness in psychological intervention trials 
is questionable. Because of the differences in the intervention set up and delivery it is 
harder for psychological interventions to score well in comparison to drug trials, e.g. 





only one facet of quality when reviewing psychological interventions studies. Many 
other important factors of quality exist, e.g. how accessible the article is or how 
clinically relevant/applicable the results are, however the Cochrane tool misses all of 
this. Whilst the RCTs in this review did not score highly on the risk of bias tool, many 
would score highly in terms of their accessibility and clinical usefulness.  
 
Limitations of this area of research 
Whilst there were enough RCTs that fell within the inclusion criteria available 
to complete this systematic review and meta-analysis, more research is needed to 
strengthen the tentative conclusions drawn and allow for subgroup analysis. The vast 
majority of RCTs on psychological interventions for BPD relate to the traditional 
interventions such as DBT which are approximately a year or more in length. Further 
research is needed to add to the number of RCTs on the medium-term CBT 
interventions and the field would benefit from some consistency in the BPD outcome 
measures used.  
  To reduce the risk of bias in this field of research future RCTs need to report 
more detail of the study methodology and improve potential reporting bias and 
selection bias. This would include publishing more studies with negative findings in 
order to reduce any publication bias that may be occurring. 
 
Clinical Implications  
 The results of this review suggest that CBT interventions between three and 
nine months are effective in reducing BPD symptoms, and that these changes are 
maintained at follow-up. The effectiveness of the intervention does not seem to be 
clearly influenced by length; RCTs which had significant outcomes had a wide range of 
intervention lengths. In relation to intervention type, it may be that DBT is less 
effective in its shorter form than the other interventions as three of the four studies 
which did not report a significant difference in BPD outcomes used DBT.  
Comparing these results to the literature, medium term interventions appear to 
be less effective than longer-term interventions, such as standard DBT, in reducing 
specific risk outcomes. This means that medium term interventions, excluding DBT, 
may be more suitable for reducing BPD symptoms globally in low risk individuals, e.g. 





e.g. in secondary care. Both medium-term and long-term interventions are likely to act 
on the same underlying processes mentioned earlier and both teach individuals emotion 
regulation skills and skills to manage their relationships. It may be that longer 
interventions allow those who engage in risky behaviours to practice and consolidate 
their skills, often with extra support, and a shorter intervention may not allow for this to 
occur even when similar skills have been taught. Medium-term interventions may also 
be more cost effective; all of the interventions in this review were primarily group 
format therefore less resource heavy than interventions with an additional individual 
therapy component. 
Many meta-analyses of DBT calculate effect sizes for suicidal and self-injurious 
behaviours specifically, whereas this review focused on BPD outcome measures. 
Whilst global BPD outcome measures may address risk issues within them, the focus is 
not specifically on risk. This may reflect a ‘lower-risk’ population being recruited in to 
medium-term interventions, both clinically and in research. 
 
 
Implications for Future Research   
 Whilst the results presented here suggest that medium-term and long-term 
interventions can both be effective for different populations, the full benefits of 
medium term compared to long-term are yet to be established. In line with this 
comparison, researchers should consider whether there is a difference in the severity at 
baseline of participants in both medium-term and longer-term interventions. Further 
research comparing medium term interventions to long-term interventions is needed to 
establish whether medium-term interventions are more time effective (e.g. greater 
change or maintenance of change) than the longer, traditional interventions. 
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The Offender Personality Disorder (OPD) Pathway faces the difficult task of 
identifying individuals who are eligible for their service from the entire probation 
caseload. The OASys Personality Disorder Screen (OASys PD) is a national screening 
tool used by the pathway to help with this task. This paper describes a quantitative 
evaluation of the effectiveness of this tool for correctly identifying eligible individuals 
for the OPD service in the South of England. The service uses an additional screening 
method involving specialist clinicians interviewing probation officers about individuals 
on their caseload. A qualitative analysis of clinician’s experience of this screening 
method is described here. Based on both analyses, recommendations to the service are 
made for using the most time-effective and clinically-effective screening process. 
Continued use of the combination of the screening tool and the interviews is 
recommended with minor adjustments.  
Keywords: OASYs, Personality Disorder, Screening, Probation, Offender 























An evaluation of the Current Screening Tools used in the Offender Personality 
Disorder (OPD) Pathway 
 
The prevalence of individuals who meet the diagnostic criteria for personality disorders 
is estimated to be around 5-10% in the general population and in excess of 50% in 
prison and forensic samples (Fazel & Danesh, 2002; Motz et al., 2015). A recent 
Swedish study reported the prevalence of Emotionally Unstable Personality Disorder 
(EID) to be 19.8% among male offenders on probation (Wetterborg, Långström, 
Andersson, & Enebrink, 2015). It has been suggested that offenders who meet the 
criteria for a diagnosis of personality disorder may be at a higher risk of committing 
serious crimes (Blackburn, 2000) and that those who meet the criteria for ‘dangerous 
and severe personality disorder (DSPD)’ have quicker reconviction rates for more 
serious offences (Coid et al., 2007). It should be noted that the DSPD term is not a 
clinical classification (Howells, Kirshnan, & Daffern, 2007). The link between the 
presence of difficulties indicative of a personality disorder and offending has led to the 
provision of services that support high risk individuals on probation caseloads which 
aim to minimise both risk of harm and social costs.  
 
Identifying Appropriate Individuals 
In order to provide an effective provision these services first need to identify the 
individuals who meet their criteria from the National Probation Service (NPS) 
caseload. There are several ways to establish whether individuals might meet 
diagnostic criteria for personality disorder; unstructured clinical interviews, 
psychometric questionnaires and semi-structured interviews such as the International 
Personality Disorder Examination (IPDE). These are time consuming and require 
training to administer which makes them unsuitable for the volume of individuals on 
the probation caseload. A national tool called the Offender Assessment System 
Personality Disorder Screen (OASys PD) is used to identify those offenders with 
particularly complex and challenging needs to bring into the service to manage and 
minimise risk. 
The OASys PD consists of is a 10-item check-list (DSPD Score) and an 





contains items indicative of diagnostic features of “Antisocial Personality Disorder and 
Psychopathy” (London Pathways Partnership, 2017). The presence of seven or more 
items should ‘indicate concern’  however over 30% of offenders within probation’s 
caseload score at or above the suggested cut off (Motz et al., 2015). The OASys PD 
was originally developed as a screen for Antisocial Personality Disorder (ASPD) with a 
Positive Predictive Value (PPV) of 85% on the initial validation prison sample (Bui, 
Ullrich, & Coid, 2016). Guidelines for the use of OASys highlight the limitation that 
traits of other diagnoses e.g. EID may be missed (Motz et al., 2015). There is yet to be 
a nation-wide evaluation of the effectiveness of this tool for correctly identifying 
individuals who meet the criteria for the specialist offender services. 
There is limited research discussing the difficulty of identifying individuals 
with difficulties indicative of personality disorder in probation samples. Minoudis, 
Shaw, Bannerman, and Craissati (2012) found that using the DSPD score alone yields a 
number too large to be meaningful and identification rates by probation officers vary 
considerably from one individual to the next. However, combining markers of 
personality problems, the DSPD items and offence severity alongside screening 
meetings between probation officers and psychologists allows for high specificity and 
sensitivity in identification.  There is also evidence that providing psychological 




The specialist offender service described here is a psychologically led service 
which is contracted to provide the National Personality Disorder Strategy (OPD 
Pathway) within three local delivery units of the National Probation Service in the 
South of England. The OPD pathway use the OASys PD screen to identify eligible 
individuals from the probation caseload. The tool is viewed by many clinicians in the 
OPD pathway to be too simplistic and to be producing too many errors (false positives 
and false negatives). Until now the above perception had just been anecdotal and no 






  The need to accurately screen for individuals with difficulties reflective of 
personality disorders does not ignore the many problems associated with the diagnostic 
construct. The diagnosis can pathologise an individual’s response to early relational 
trauma and is associated with significant stigma. The OPD pathway recognises this and 
does not require a formal diagnosis for individuals to be eligible for their service, 
however a screening tool associated with this diagnostic construct is necessary in order 
to provide an effective service to the correct individuals.  
In response to the perception of the OASys PD tool being too simplistic the 
OPD pathway implemented an additional screening process; interviewing probation 
officers about their caseload to identify those with complex/challenging needs that 
could be considered to reflect a diagnosis of personality disorder. The screening 
interview is a lot more time consuming than the OASys PD tool, taking 1-2 hours plus 
additional admin time (per probation officer caseload). An evaluation of this new 
process was indicated so that the most time-effective and accurate process for 
identifying eligible offenders is used. 
 
Aims  
The project was split into three stages. The aims, and any associated research 
questions, of these stages were: 
1) Establish how the OASys PD tool compared to clinical judgement about 
appropriateness of an individual for the OPD service 
• How accurate is the OASys tool at correctly identifying individuals who need 
the service? The service hypothesised that the OASys was missing 10-15% of 
individuals who needed the service. 
2) Establish clinicians experience of the screening interviews 
• Are the screening interviews helpful and can they be improved? 





Evaluation Part 1: OASys Analysis 
Method 
Sample and data collection. 
Both Research and Development (R&D) approval from the NHS trust and 
ethical approval from the University of Bath were gained for both part one 
(quantitative) and part two (qualitative) of this evaluation.  
Anonymous data on the outcome of the screening tool was provided by the 
service e.g. the individual was screened in when they met seven or more of the items on 
the DSPD checklist or the presence of two of the four additional criteria, and otherwise 
screened out.  This was compared to data provided on the subsequent pathway of the 
individual (e.g. whether they were actually brought into the service or were screened 
out at a later date). The data came from 1368 individuals from four geographical areas 
covered by the service and is routinely collected by the service. Each data point was 
given a code from 1-4.  
 
Table 1 
Codes used during data analysis 
Code Meaning  
1 True positives, where the OASys PD screened them in and they were 
deemed suitable/remained in the service 
2 False positives, where the OASys PD screened them in but they were 
later screened out/not deemed suitable for the service 
3 False negatives where the OASys PD screened the individual out but 
they were later brought into service/deemed suitable by a different 
process e.g. screening interviews 
4 True negatives where the OASys PD screened them out and they 
remained out of the service/not suitable 
 
After the initial coding 10% of the data was double-checked to ensure integrity 
of the coding. Totals of codes 1-4 were calculated and used to calculate the Positive 
Predictive Value (PPV) and Negative Predictive Value (NPV) of the OASys PD screen. 
PPV refers to the probability that an individual with a positive screening test truly has 
the ‘disorder’.1 PPV was calculated using the following equation; True positives/(true 
                                                
 
1 These terms are from medical statistics. In this research, a positive result meant that the 
individual met criteria for the service and were appropriately screened in, rather than ‘truly 





positives + false positives). NPV refers to the probability that an individual with a 
negative screening test truly does not have the ‘disorder’.2 NPV was calculated using; 
True negatives/(true negatives + false negatives).  
 
Results 
Data from one of the four probations areas was excluded due to the extensive 
number of data gaps. Data gaps occurred where there was not sufficient information 
recorded to identify the pathway of the individual in or out of the service. Data gaps 
from the other three areas equated to 17% of the total data points. Data from a total of 
1179 individuals, from three probation areas, was used in the final analysis. 
Analysis revealed a PPV of the OASys PD Screen of 72%. This means that for 
the data analysed a positive result on the OASys screen would have correctly identified 
an individual who did need the service 72% of the time. The NPV was calculated to be 
91%. For the data analysed a negative result on the OASys screen would have correctly 
identified an individual who did not need the service 91% of the time. Table 2 shows 
the total numbers of True Positives, False Positives, False Negatives and True 
Negatives respectively. 
Evaluation Part 2: Clinician’s View of Screening Process 
Method 
Participants and data collection. 
A pool of 14 clinicians from the OPD service were invited to participate in a 
focus-group on the experience of the screening interviews and the screening process. 
Eligibility criteria were that the individual was a member of the OPD service who had 
experience of conducting screening interviews with probation officers; all 14 invited 
clinicians met this criterion. Clinicians were provided with information on the purpose 
of the group and the proposed interview schedule (see Appendix D) by email and were 
asked to confirm their interest in participation before the day of the focus-group. Six 
individuals confirmed their interest in the focus-group prior to participation and five  
                                                
 
2 Similarly, a negative result would mean that the individual had appropriately been screened out 







Total numbers of screening outcomes. 
Type Number identified % of Total 
True Positive 556 47 
False Positive 214 18 
False Negative 35 3 
True Negative 374 32 
Total 1179 100 
 
individuals took part on the day. 
The focus-group lasted one hour and took place at the end of a Team Away 
Day. The focus-group was facilitated by the lead researcher (ZM) using a semi-
structured interview protocol and was audio-recorded. Written consent was obtained 
from all individuals.  
Analysis. 
The focus-group was transcribed and analysed using the Classic Framework 
Analysis Approach described by Krueger and Casey (2009). This approach was chosen 
due the advantages of a systematic approach to analysis that was designed specifically 
for focus-groups. The epistemological stance of the researcher conducting the analysis 
was of Critical Realism. Once the main themes and sub-themes had emerged these 
were checked with a second researcher and shown to individuals in the service with the 
opportunity to comment/feedback on them. 
 
Results 
Analysis of the focus groups revealed a number of key findings which are 
summarised in relation to three questions. The themes in relation to Question 1 (What 
works well about the screening interviews?) were; providing reflection on cases, 
increasing awareness of probation staff and fulfilment of core roles of the service (see 











Figure 2. Diagram of Themes (Left) and Subthemes (Right) in relation to Question 2 
 
 
                                            
Figure 3. Diagram of Themes in relation to Question 3 
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The themes identified in relation to Question 2 (What is difficult about the 
screening interviews?) were; use of resources and relationship management (see Figure 
2). The themes identified in relation to Question 3 (How could these be improved?) 
were appropriate spacing and conducting the interviews in pairs being suggested as 
improvements (see Figure 3). These themes are elaborated and discussed, with 
reference to quotes from the focus-group, below. 
What Works Well about the Screening Interviews? 
 
Theme: Reflection   
Providing supervision space. 
Clinicians reported that the addition of the screening interview adds value to the 
screening process as it provides time and space for Offender Managers (OMs) to reflect 
on their caseloads in a supervision setting that they may not otherwise have access to.  
PP1: “I think it’s the space to reflect as well, it’s a proper time out. They’ve booked 
two hours out to sit with us so they’re literally having that two hours to think about the 
cases rather than answering the phone or somebody is coming and they just have that 
time, and they don’t get that in supervision” 
PP2 “they’re (OM) appreciative of that time and space, it’s a little bit forced upon 
them, that time and space to actually think about the individual and think about what 
their needs are and their pathway” 
Thinking differently. 
This space for reflection allows for thinking in a different way about the 
offender, or about different ways to engage or work with offenders, which participants 
said can help to bring about change in cases that can otherwise appear stuck.  
PP3: “with certain cases they have just got a bit lost and not being progressed 
through. People can start thinking about them [cases] again in a slightly 
different way to maybe ‘Are they just messing up?’” 
PP4: “and it just enables that space to sit down and think outside the box about how to 






Theme: Increasing Awareness  
Personality disorder awareness. 
A major theme reported by the clinicians was the upskilling of OMs in terms of 
their knowledge and understanding of working with the client group (individuals with 
symptoms indicative of a personality disorder).  
PP5: “it was a positive experience, the OM (was newly qualified. It felt good to engage 
her in understanding what PD is, so it felt like you were giving over information.” 
PP1: “I think if you are adding that value as well that’s what our project 
should be about and kind of raising awareness for the OM to understand more 
about personality disorder and how it might manifest itself or how it might 
show itself” 
PP4: “…you’re actually up skilling people and helping them to think about their 
caseloads, just for those who are less used to talking about PD”” 
Service and role awareness. 
Clinicians also described that the screening interviews allowed the OMs to learn 
about the Pathfinder service and the roles of the clinicians and what they can offer. As 
this knowledge has been given over time the screening interview process has been 
described as becoming easier.  
PP1: “when we were first going in to do screenings with probation officers and they 
didn’t quite understand it so, and they haven’t experienced actually what a 
consultation, what a formulation, what other sort of pathway planning stuff actually 
could add to the supervision of their cases.” 
PP4: “So it’s actually a really good opportunity for them to start understanding what 
we can offer in terms of a service and I think that’s always a bit of a relief to people; to 
go away thinking someone, in a way, is going to take something off my hands, or I 
don’t have to think about this case on my own” 
 
Theme: Fulfilment of Core Roles 
Identifying appropriate clients.  
The opinion emerged that the identification of individuals with personality 
disorder is improved using the screening interviews compared to screening just using 





PP2 “[The OASys PD] kind of misses a lot, I mean relationships isn’t- there’s nothing 
on relationships which is kind of an obvious thing like what would be an issue for 
somebody with personality disorder.” 
PP3: “I’m just thinking in terms of a tool, if you just do them as tick box it doesn’t 
really have, it doesn’t tell you a wealth of information…… Personally in terms of tick 
box and the score I just do it because we have to, I wouldn’t say that I have confidence 
that it always gets it right” 
Identifying pathways. 
Clinicians reported that the screening interview can provide a wealth of 
information from which can help to identify the individual’s pathway earlier.   
PP3:” we are trying to get as much done in that screening process as possible… 
so we can do a bit of consultation, we can identify a pathway for the person 
that’s been screened in, we can start to identify where they are going” 
Identifying needs. 
The screening interviews were seen to provide an opportunity for OMs 
to recap their entire caseloads and for clinicians to gain a sense of the needs of 
both the service users (e.g. needs of an offender being screened in) and the 
OMs (e.g. where an OM might need support to understand and recognise signs 
that an offender is eligible for the service). 
PP4 “I think that that’s probably the key thing with screening; it identifies 
that caseload but it also helps us identify exactly what the needs are.” 
PP3 “It’s also a bit of an opportunity for them (OMs) to have a recap on their 
cases. So actually it can be a bit of reassurance of actually knowing where 
everybody is at ‘cause I’ve had that recap of it. I think that’s a really 
functional aspect of it” 
 
Time-effective. 
Whilst the screening interviews take longer than just using the 
screening tool, the process is described to be time-effective as the 
identification of pathways/consultations can occur earlier. Clinicians also 
reported their experience that if the process is done well the piece of work can 





PP2 “And the screening meeting will feed into pretty much all but one of our objectives 
for commissioning, so it’s a major piece of work that if you’ve done it effectively, I hate 
using this term, but it ticks boxes. So yeah it can be very effective but also time 
consuming” 
PP3 “Yeah I do think that if you do it to a certain level actually that piece of work on 
its own with that case can then last for potentially 12 months until the next review” 
 The participants in the focus-group described their overall experience of the 
screening interviews as positive and helpful, but made reference to the below 
difficulties.  
What is Difficult About the Screening Process? 
Theme: Relationship Management 
Personality disorder dynamic. 
Clinicians described that the working relationships between the pathfinder 
clinicians and the OMs to be difficult to manage at times. Clinicians described that 
transference of the dynamics between the offender and the OM could be mirrored in the 
relationship between the OM and the clinician.  
PP4 “I think the thing that I would find most difficult, and most worrying in 
terms of if we were leaving some people to it, I suppose in that way is those who 
very clearly have a PD dynamic going on in the relationship that they have with 
the offender but that is not clear to them in any way shape or form because 
they’ve become so immersed in it and so blind to what is going on” 
Difficult conversations. 
Having difficult conversations, such as bringing a dynamic to the OM’s 
awareness or highlighting an area where perhaps the OM lacks some knowledge, were 
described to be challenging by clinicians due to the need to be sensitive and non-
shaming. 
PP3: “…you have to be quite skilled about not shaming OMs about their 
knowledge about their cases.” 
PP4 “That can sometimes be a very difficult balance to strike and having to 
tread very carefully sometimes, particularly I think where there are people who 





it that they also don’t realise that they know so little about it, and that’s where 
the difficulties arises” 
Negative reactions. 
Staff-burnout and lack of capacity due to ever increasing demands was 
described as one of the reasons that OMs could sometimes have a negative reaction to 
the screening process. Reactions experienced include OMs being defensive about their 
caseloads, not being open to suggestions and devaluing the OPD clinician’s role.  
PP2 “Yeah I’ve had a couple of people like that who are quite defensive about their 
cases, it was hard. And I’ve had people that have devalued our role….so they have felt 
that they really don’t want to give their time to screening because they are so busy 
doing important stuff.” 
PP1: “You get a sense of ‘none of my cases are PD, leave them alone, they’re all mine’ 
kind of thing. Just kind of presents a bit defensive.” 
PP4 “I think its when people have got to the point that they’ve become very cynical or 
very burnt out or whatever.” 
 
Theme: Use of resources 
 Occasional redundancy/over-resourcing.  
It was noted by participants that there is of course variation in the experience of 
the screening interviews, for example there are OMs who already have a lot of 
knowledge of personality disorder/the service or where the screening interview isn’t 
deemed useful. 
PP2: “the others it was kind of almost obvious when you’re looking through, you just 
think this is really obvious and you almost think is it worth taking up like an hour and a 
half or two hours of their [OM] time to have them in a room when you could just be 
doing it yourself” 
Administration time. 
Clinicians reported that whilst the screening as a whole is time-effective in the 
long run, the process is resource heavy and that the associated administration time is 





PP3: “I suppose the thing is that for us as clinical staff… there is a lot of admin so I 
think It does feel like a laborious process because there is big admin aspect to it. And 
you tend to think ‘I shouldn’t be doing admin I should be doing something else” 
PP4 I think the meeting itself is time effective, it’s all the admin that goes around it that 
we’ve all been struggling with….” 
Emotional load of caseload review. 
The screening interviews were also described as resource heavy and draining 
from a personal point of view for both OMs and OPD clinicians. The volume and 
nature of information that is being given over in the 2-hour interviews was described to 
be draining.  
PP3: “I do sometimes get concerned that as you go through you can chat 
about 20-25 cases all high-risk offenders, all committed quite- sort of yeah 
nasty offences, and personally sometimes going through doing the screening 
stuff you’re like that’s a lot of information to hold, I think probation officers 
sometimes they don’t want to hold all that information for all their cases they 
are responsible for at the same time… sometimes yeah if you’re brining it up 
and going through sometimes it can be quite a draining process again.” 
Information overload. 
The repetitive/similar nature of many of the cases can mean that information is 
forgotten or confused if too many are done together.  
PP2: “So we’re screening in, giving them information that they probably 
don’t even want to hold in their head, so it can be a bit of an obstructive 
process for them”” 
PP1 “You can even start to forget which case is which as you are doing them. 
You’re talking about somebody a minute ago who was a [convicted of] 
domestic violence and you might still have the [man convicted of] domestic 
violence (man) in your head because you’ve done so many that day” 
How Could These be Improved? 
Theme: Appropriately Spaced 
Spacing out the interviews was seen to allow for enough time to write up the 





PP2: “I think you’ve got to be organised in how many you allocate yourself because if 
you’re not dong it right it becomes ineffective. So if you’re doing lots of screening and 
you are not able to upload that data then you forget.” 
PP1: “you need to have a few breaks in between. That’s probably why it 
works well in pairs because you switch over.” 
 
Theme: In Pairs 
Conducting the screening interviews in pairs, as they have sometime been done 
in the past, was suggested by clinicians to help reduce the negative impact of the 
volume and type of information being discussed, help with having the difficult non-
shaming conversations with OMs and allow for two people’s heads to be thinking 
about the same person.  
PP3: “I think when you’re done you feel exhausted afterwards, whereas it’s not that 
level of exhaustion in a pair, cause you do tag team naturally.”  
PP4 “I actually really valued doing them in a pair, because partly of what PP1 was 
saying about kind of the objectivity and stuff about it but sometimes you do get cases 
that you are discussing when it isn’t really very clear sometimes its just to have that 
additional person to check in… and again I think that’s where its really helpful to have 
two people doing it rather than one because there may be times when you really need 
to pause to think about how you say things and how you approach things. “ 
Stage 3: Feedback and Recommendations  
 
The results (Table 3) of the evaluation were fed back to the service in a 
presentation at a team away day. The results were discussed and the team drew up an 
action plan for recommendations The results suggest that the additional screening 
interview will at most pick up a potential extra 3%. It is not certain that the screening 
interview actually picks these cases up; the service did not record how false negatives  
were eventually identified, so although it is likely to be through screening interviews, 
this is not definitive. The team reflected that the results and discussion were extremely 
helpful and that they had been shocked to hear that their hypothesis that the screen was 
missing 10-15% of eligible individuals was not confirmed. A potential reason for this 






Summary of Results fed back to the service 
Key Results 
• For the population analysed, the tool alone accurately identified individuals who 
were eligible for the service 79% of the time 
• 3% of individuals were ‘missed’ by the screen (false negatives).  
• 18% of the individuals were screened in when the tool was over-inclusive (false 
positives)  
• The screening interviews do have value in addition to identifying possible false 
negatives; they allow for reflective space, increase awareness and help to fulfil core 
roles (e.g. commissioned duties including providing a psychologically informed 
service for challenging, high risk group)  
 
might miss (e.g. individuals with traits indicative of EID). These cases were described 
to feel ‘bigger’ in some way, e.g. take up a ‘big space’ in the mind due to added 
emotional weight of the case, so clinicians felt they may have over predicted the 
number of cases to reflect this. Table 4 shows the recommendations discussed and the 




Contrary to team expectations the resource-intensive screening interviews were 
not identifying as many extra cases as predicted, although the false negatives were 
believed to be significantly emotionally intensive. The screening interviews were seen 
to be valuable in a number of other ways and the team has taken forward 
recommendations based on these results to refine the process whilst managing some of 
the challenging elements. 
 
Implications 
The analysis of the tool’s ability to correctly identify individuals who clinicians 
feel meet the criteria for the OPD service offers an initial piece of evidence towards the 
validity of the use of this tool. The National Offender Management Service note that of 
the number of screening tools available only one (the Standard Assessment of 
Personality- Abbreviated Scale [SAPAS]) has been tested for validity and that 






Summary of recommendation and agreed actions from the service 
Recommendation Rationale Action Points 
A further piece of work be 
undertaken to track where the 
false negatives are picked up (e.g. 
whether they are being screened 
in or highlighted in the screening 
interviews or not) and the profile 
of these individuals. The database 
should be completed in a uniform 
way across all areas for any future 
analysis.  
 
This would provide evidence 
for whether discussing the 
false negatives in the 
screening interview has any 
value, whether the false 
negatives are high-risk and 
could help build an 
understanding of the OASys 
blind spots.  
Previously data had to be 
excluded due to missing 
information.  
Passed on to the 
service lead 
Continue running the screening 
interviews but streamline them by 
initially only discussing 
individuals with a ‘positive‘ 
screened in result from the tool.  
The screening tool is over-
inclusive and correctly 
identifies true negatives more 
often than true positives. 
Therefore the positive results 
should be discussed during 
screening to identify which are 
true and which are false. This 
recommendation allows the 
benefits of the screening 
interview to continue but will 
require less resources 
 
Agreed to take this 
recommendation 
forward and initially 
discuss those 
individuals with a 
positive screen 
In line with the above 
recommendation, offer the OM 
the chance to bring any other 
individuals to the screening 
interview that they are concerned 
about, in addition to the ‘positive’ 
screened results 
This will allow for any 
possible ‘false negative’ 
individuals to be discussed 
and maintains discussions of 
individuals who may not be 
eligible for the service, but the 
OM requires help with (which 
improves good working 
relationships) 
Agreed to take this 
recommendation 
forward and will /offer 
the chance for the OM 
to contact the clinician 
about other cases that 
are concerning as 
needed.  
 
A guideline of one hour to one 
and a half hours of screening per 
session be recommended to 
clinicians 
This will reduce the chances 
of information overload so 
that the clinicians can be time-
effective 
Agreed to set this 
guideline but 
recognise that staff 
may choose to do 
more or less when it 
suits their diary 
 
Run the screening interviews in 
pairs where possible  
To reduce the emotional load, 
information overload and help 
with difficult conversations 
during the screening 
interviews 
Agreed to run the 
screening interviews in 








in a probation sample, using the recommended cut-off score of 3, the SAPAS has a 
positive predictive value of 96% (Pluck, Sirdifield, Brooker, & Moran, 2012) which is 
slightly higher than the OASys PD result described here. However, the results 
described here suggest that the OPD team use a screen (OASys PD) with caution (the 
addition of the screening interviews) which creates a useful and effective process for 
tackling the very difficult task of delivering the service to the target population. Most 
importantly the OASys PD rarely identifies false negatives and therefore the risk of a 
potentially dangerous individual not receiving the service that they need is very low.  
The team felt that a PPV of 79% and a NPV of 97% were acceptable/usable for 
two reasons. The team had expected the tool to be performing poorly and to be missing 
10-15% of cases (expected NPV 85-90%) so the results were an improvement on this. 
Secondly, the tool is over-inclusive, so the errors that it makes do not increase risk and 
a key role of the service is risk management.  
The team feedback session highlighted the difficulty that the OASys screen has 
for picking up difficulties indicative of the entire range of personality disorders, e.g. 
Dependent Personality Disorder, due to the development of the screen stemming from 
the identification of antisocial personality disorder. Whilst an important limitation to 
consider, the OASys is not alone in its difficulty to identify all types of personality 
disorder equally well. The SAPAS is noted to correlate less well with antisocial, 
narcissistic, and histrionic personality disorder traits (Hesse & Moran, 2010). This may 
reflect the heterogeneity of the traits which fall within the differing personality disorder 
constructs. It may therefore be best practice to use a tool which correlates highly with 
the type of traits that are prevalent in the population, as the OPD team does, and hold in 
mind these limitations. 
 
Limitations 
The results described above only represent how likely that a positive result 
represented a true positive, and vice versa, for the population analysed; if the OASys 
screen was used on a different population, the PPV and NPV would change. The PPV 
and NPV are directly influenced by the prevalence of the disorder in the population 
(Parikh, Mathai, Parikh, Sekhar, & Thomas, 2008) and it is noted that the OASys is a 





It is also necessary to comment on the noticeable limitations that this medical 
model analysis presents by classifying personality disorder as a ‘clinically present 
disorder’ that is present or not. There are the aforementioned difficulties with the 
diagnostic construct however there needs to be a way to filter out those less likely to 
have difficulties indicative of a personality disorder from the large number of high risk 
of harm individuals.  
The missing information that resulted in certain areas and data points being 
excluded from analysis appeared to be related to different individuals/localities 
recording different amounts of information in different ways on the database. The data 
gaps highlight the need for the entire service to populate the database in a uniform way 
should future research be pursued. 
The focus-group was completed with five individuals however only four 
contributed significantly to the interview. The fifth individual had less experience of 
screening, was new to the team and had less established working relationships with the 
others which may explain their reduced participation. Whilst the results of the focus-
group naturally only reflect the views of those involved, other team members were 
present at the feedback session and no concerns or challenges were raised.  
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Objectives: This study aimed to explore whether mental defeat (MD) occurs in long 
term health conditions (LTCs) and if it does, whether it differs across conditions with 
differing symptomology.  
Design: This study used a cross sectional questionnaire design with two groups; 
Inflammatory Arthritis (IA) and Chronic Kidney Disease (CKD).  
Methods: Participants in both groups completed a battery of questionnaires about their 
experience of, and their beliefs and feelings about their health condition. A mixed 
model ANOVA and stepwise regressions were conducted to explore associations.  
Results: A mixed model ANOVA revealed no significant differences in levels of MD 
between the two groups. However, both groups reported higher levels of MD than 
healthy controls. A stepwise regression revealed that MD, health anxiety, disability and 
catastrophizing were all associated with psychological distress. A second regression 
revealed that MD, age, and health anxiety predict fear of disease progression. 
Conclusion: Mental defeat occurred in both LTCs in this study and there was no 
difference between the two conditions. Mental defeat was associated with 
psychological distress and fear of disease progression.  





















Mental Defeat in Long Term Health Conditions 
 
Long term health conditions (LTCs), defined as conditions that cannot be presently 
cured but are controlled by medication or other treatment, are common and debilitating. 
LTCs are reported to effect around 14% of individuals under 40 and 58% of those 60 
and over (Department of Health, 2012; Office for National Statistics, 2009). Individuals 
with LTCs often have comorbid mental health difficulties such as anxiety and 
depression (30%) and can experience poorer health outcomes and quality of life as a 
result (Naylor et al., 2012). Research has begun to consider the psychological process 
which may be involved in psychological complications of LTCs. 
Health Psychology research has recently explored the role of Mental Defeat 
(MD) as a process contributing towards psychological distress in certain LTCs. Mental 
defeat (MD) is a cognitive phenomenon first described in relation to Post Traumatic 
Stress Disorder (PTSD) and depression and it has been linked to the development and 
maintenance of PTSD symptoms, as well as being associated with greater symptom 
severity and poorer treatment response (Dunmore, Clark, & Ehlers, 2001; Ehlers et al., 
1998; Gilbert & Allan, 1998). Ehlers et al., (1998) suggested that MD results in an 
individual giving up their effort to maintain their self-will and identity through a 
perceived lack of autonomy in the face of traumatic and uncontrollable events. 
MD can be distinguished from both helplessness and hopelessness. 
Helplessness refers to the lack of relationship between an individual’s behaviour and 
the reward/stimuli. An individual who experiences torture where there is no link 
between their behaviour and the consequence may feel helpless but can still retain a 
sense of their identity and a sense that their will is separate to that of their attacker 
(Ehlers et al., 1998; Tang, Salkovskis, & Hanna, 2007). Hopelessness, defined as an 
expectation that the desired outcomes will not occur, is related to future events as 
opposed to ones sense of self (Tang et al., 2007). Not all individuals who experience 
multiple traumatic events against their will develop MD. MD is a cognitive process 
which can contribute to low mood and depression however it differs to depression in its 
focus. MD has a narrower focus on the self/identity than depression which incorporates 
more global judgements. More recently MD has been shown to be associated with low 
self-efficacy (whilst being described as ‘the opposite of self-efficacy’) and to differ 





Osborn, & Gauntlett-Gilbert, 2018). Whilst parts of the construct overlap with many 
other existing psychological concepts, MD is unique in its own right. 
 
Chronic Pain 
The concept of MD has more recently been explored in relation to chronic pain. 
Experiencing chronic pain has been likened to some trauma experiences as it can be 
repeated, unpleasant and perceived as outside an individual’s control. Tang et al. (2007) 
define MD in relation to chronic pain as “a disabling type of self-processing where 
repeated episodes of persistent and debilitating pain trigger negative beliefs about the 
self in relation to the pain” (page 222) and have found elevated levels of MD in chronic 
pain patients compared to control groups. MD has also been indicated an important 
mediator of distress and disability (Tang, Goodchild, Hester, & Salkovskis, 2010) and 
as a predictor for heightened suicide risk in individuals with chronic pain (Tang, 
Beckwith, & Ashworth, 2016). A negative appraisal of the pain can lead to both 
negative beliefs about the self, increased psychological distress and reduced 
activity/increased disability (Beck, Rush, Shaw, & Emery, 1979; Lewishohn, 1974).  
Research suggests a link between MD and treatment seeking; individuals who 
were seeking treatment for their pain had significantly higher levels of MD compared 
to non-patient volunteers matched on pain (Tang et al., 2007; Ziegler & Paolo, 1995). 
This suggests that emotional distress effects treatment seeking behaviours more so than 
the level of pain experienced by the individual. This has important implications not 
only for the self-management of patients with chronic pain but also the associated costs 
to the health service e.g. from repeated medical visits.    
MD has been likened to a type of catastrophising focused on the self, the 
person’s life and their identity. Whereas general catastrophising (in relation to pain) is 
focused on what the pain means for the person in terms of their health (Tang et al., 
2007). 
The cognitive theory underpinning research into MD and chronic pain can be 
applied to other health conditions where an appraisal-based model can help to 
understand the psychological experience for the individual. If mental defeat does occur 
in other LTCs it may be a cognitive process that affects treatment seeking, suicidality, 
symptom severity, and levels of distress, making it a useful area for research to both 





the present paper MD is explored in two LTCS that differ in presentation and pain 




Inflammatory arthritis (IA) is the collective term for the two conditions; 
Rheumatoid arthritis (RA) and Psoriatic Arthritis (PA). RA is chronic autoimmune 
condition involving pain and inflammation of the joints which affects around 1.16% of 
women and 0.44% of men in the UK (Nyklíček, Hoogwegt, & Westgeest, 2015; 
Symmons et al., 2002).  PA is a similar condition which is associated with skin lesions 
and affects approximately 0.1-0.3% of the UK population (NICE, 2009). The trajectory 
of IA is variable however in aggressive forms the conditions can be disabling, with 
erratic symptom flare ups and chronic stiffness and swelling of joints (NICE, 2009; van 
Riel, van Gestal, & van de Putte, 1996). As a result, psychological distress (at a higher 
rate than the general population) associated with the incurable and unpredictable nature 
of the disease is common (Nyklíček et al., 2015). Prevalence rates of either depression, 
anxiety or comorbid depression and anxiety have been estimated to be just over 40% of 
assessed patients with RA (Covic et al., 2012). Research exploring the impact of 
chronic health conditions on major depressive disorder in adults named RA as the 
greatest relative contributor for adults over the age of 60 (Ryu et al., 2016). 
 It is hypothesised that MD (self-catastrophising) may occur in individuals with 
IA due to repeated exposure to pain and possible isolation due to reduced mobility and 
irregular, infrequent hospital appointments. Research also suggests that individuals 
with IA are faced with the task of reconciling threatened personal goals (Arends, Bode, 
Taal, & van de Laar, 2016) which suggests that personal identity and sense of self are 
affected which both have a role in MD.  
Health psychology recognises that catastrophising beliefs, where patients may 
over-estimate the degree of emotional distress that they are in and overly focus on the 
negative aspects and potential outcomes of an illness, are common in chronic pain 
conditions (Straub, 2014) including IA (Keefe, Brown, Wallston, & Caldwell, 1989). 
Due to the unpredictable but potentially debilitating prognosis of IA, it is expected that 






Chronic Kidney Disease 
Chronic kidney disease (CKD) is a long term condition affecting around 4.7% 
of adult males and 7.4% of females in the UK (Public Health England, 2015). CKD is 
more common in older age and has five stages starting with very minimal symptoms in 
early stages, progressing to fatigue, nausea and shortness of breath in later stages and 
the need for dialysis/transplant in final stage renal failure (Chronic Kidney Disease 
Treatment, 2016). In comparison to IA, pain is not a prominent symptom of CKD and 
individuals in early stages can be asymptomatic (Arora, 2017). Whilst the trajectory 
and timeline for both LTCs is unpredictable and uncertain, in CKD there are clear 
stages and associated monitoring/treatment pathways. It is hypothesised that these 
factors may mean that MD occurs less in CKD than in IA. The experience of the illness 
may be less likely to be appraised in relation to a lack of psychological autonomy or a 
negative reflection on themselves if there is an increased perception of control via 
attending for monitoring/treatment. Attending for treatment may also make it more 
likely that an individual will interact with others with the same experience and this may 
make the appraisal less about themselves as an individual and more external.  
As with IA, CKD is unpredictable in its prognosis, with some patients 
progressing quickly through to end stage renal failure and other patient’s remaining in 
an earlier stage (Baek et al., 2012). It is anticipated that there will be general 
catastrophising beliefs about the illness and its potential progression/negative outcomes 
for an individual.  
Alongside MD and psychological distress (depression and anxiety) there are 
other psychological constructs which have been studied in health psychology and are 
known to influence an individual’s experience of living with a LTC. Anxiety-related 
constructs include Fear of disease progression and Health anxiety. Fear of disease 
progression has been suggested to be central to a patient with a LTC’s heightened 
anxiety (Herschbach et al., 2005) and has been shown to play an important role in 
individuals with rheumatic conditions (Wiener, 1975). Health anxiety is different to 
fear of progression in that it is characterised by a preoccupation/hypervigilance with 
having a serious health concern despite medical reassurance, as opposed to concern 





Aims and Hypotheses 
This research aims to explore whether MD occurs in LTCs and whether it 
differs between conditions, in order to inform psychological treatments targeting 
psychological distress in LTCs. 
Primary Hypothesis 
 There will be higher levels of MD in arthritic patients than renal patients (due 
to the difference in symptoms and treatment) but there will be no difference in levels of 
general catastrophizing (due to the chronic yet uncertain nature of both diseases). 
Secondary Hypotheses 
2a) Psychological distress will be associated with mental defeat.  
2b) Fear of disease progression will be associated with health anxiety.  
MD has been found to predict depression in individuals with Multiple Sclerosis 
(MS) and in cancer patients (Brown, Gregory, & Dysch, 2017). Health anxiety is 
associated with fear of disease recurrence in cancer survivors (Grozdziej et al., 2015). 
Methods 
Participants 
1) IA Group. Participants with IA were recruited from NHS outpatient clinics in 
Bristol and online via advertising on social media (Facebook and Twitter). 
Participants were included if they were aged 18 and over, were English speaking 
and had either Rheumatoid Arthritis or Psoriatic arthritis (diagnosed in outpatient 
settings, self-reported online). 
2) CKD Group. Participants with CKD were recruited from NHS outpatient clinics 
in Bristol and online via advertising on social media. Participants were included 
if they were aged 18 and over, English speaking and had Chronic Kidney Disease. 
Patients were excluded if they had a Glomuler Filtration Rate (GFR) score of 30 
or more, were receiving dialysis or had received a transplant. The GFR score cut 
off was used to screen out individuals attending the clinics with acute kidney 
damage. The patients in the final stage of CKD (on dialysis/transplanted) were 
excluded due to the expected heterogeneity in illness experience across the stages 
(e.g. experiencing fatigue, hypertension and attending clinics for dialysis multiple 









This study used a cross sectional questionnaire study with two groups; IA and 
CKD. The IA group was chosen because of the presence of pain in in the 
symptomology. A control group of a similar age, with a chronic condition not 
characterised by pain was required for comparison, therefore CKD was chosen. An a 
priori power analysis completed using G*Power calculated a total required sample size 




To support or disconfirm the primary hypothesis a 2x2 mixed model ANOVA 
was completed looking for an interaction between MD and catastrophising and group 
(IA or CKD). 
Secondary Analysis 
 Two stepwise regressions investigated predictors of psychological distress and 
fear of disease progression.  
1. Psychological distress (DV) with IVs; MD, age, level of disability, pain, 
HA, general catastrophizing 




Once screened for eligibility, and informed consent obtained, participants 
completed a battery of questionnaires either online or on paper in clinics (with the 
option of returning them via prepaid envelopes). Participants then received debrief 
sheets and a small donation was given to charity on their behalf to thank them for their 







The questionnaires were piloted with people with personal experience (PPE) of 
both LTCs before data collection started.  
Background Information. 
After completing screening questions (see Appendix H) participants were asked to 
provide information regarding demographics, comorbid physical and mental health 
conditions, and how well managed/burdensome they found their condition (see Appendix 
I).  
Target Measures  
Mental Defeat. 
The Pain Self-Perception Scale (PSPS) was devised to measure mental defeat 
linked to chronic pain (Tang et al., 2007). It was developed from the PTSD and 
Depression literature (Dunmore, Clark, & Ehlers, 1999; Gilbert & Allan, 1998). 
Participants read 24 statements and then rate the extent to which they apply to their 
experience on a 5-point scale (0 = never to 4 = very strongly). A total sum score from 0 
to 96 is created. There is no cut off score to suggest the presence of mental defeat or 
not, rather a higher score signifies higher levels of mental defeat.  The PSPS Scale was 
easily adapted for IA/CKD by editing the line ‘because of the pain’ to ‘because of my 
IA/CKD’ which comes before each statement.  
Catastrophising. 
The Beliefs About Physical Illness Questionnaire is a novel measure that targets 
cognitive beliefs about physical symptoms using adapted items from other validated 
CBT measures. It consists of statements which participant rate on a 10-point from 1 = 
Strongly Disagree to 10 = Strongly Agree. Eight of the 22 items (questions 5-8 and 11-
14, Cronbach’s a= 0.87) which target catastrophizing beliefs were used to create a 
catastrophising score with higher scores indicating higher catastrophising.  
 
Descriptive Measures for Secondary Analysis  
Fear of Disease Progression. 
 The Fear of Progression Questionnaire Short Form (FoP-Q-SF) comprises 12 





and reliable for use clinically and in research (cronbach’s alpha =0.87; Mehnert, 
Herschbach, Berg, Henrich, & Koch, 2006). 
Health Anxiety. 
 The Health Anxiety Inventory Short Form (HAI-SF) consists of 14 questions 
where the individual picks 1 of 4 statements, rated on a 0 – 3 scale. Higher total scores 
indicate higher levels of health anxiety.  The HAI is a reliable and valid measure of 
health anxiety and a useful screening tool (Salkovskis, Rimes, Warwick, & Clark, 
2002). A cut off of 15 is suggested to indicate the presence of health anxiety and a cut-
off of 18 identifies those fulfilling the DSM-IV diagnosis for hypochondriasis.  
Disability. 
 The Work and Social Adjustment Scale (WSAS) is a simple measure consisting 
of 5 statements rated on an 8-point scale from 0 = not at all, to 8 = very severely.  Total 
scores range from 0 to 40 and greater scores indicate greater impairment. The WSAS 
has been shown to be a reliable and valid measure of impaired functioning (Mundt, 
Marks, Shear, & Greist, 2002). 
Pain.  
The Short Form McGill Pain Questionnaire (SF-MPQ) comprises 15 
descriptions (11 sensory and 4 affective) ranked on a 4-point scale  from ‘none’ to 
‘severe’ and gives consistently high correlations to the standard form (Melzack, 1987). 
A sensory pain score is calculated by summing the sensory items and an affective score 
from the affective items. Internal consistency in RA patients has been estimated to be 
high (cronbach’s alpha = 0.73-0.89; Burckhardt & Bjelle, 1994). Content validity of the 
SF-MPQ has also been found to be good for RA patients (Burckhardt & Bjelle, 1994). 
Psychological Distress. 
 The Patient Health Questionnaire-9 (PHQ-9) is a self-report measure of 
depression comprising 9 items and giving a total score of 0-27. It has been 
demonstrated to be a valid and reliable measure in both clinical practice and research, a 
cut-off score of 9 is commonly used to indicate the presence of depression. Scores of 5, 
10, 15, and 20 represent mild, moderate, moderately severe and severe depression 
respectively. (Kroenke, Spitzer, & Williams, 2001).  The Generalised Anxiety 
Disorder-7 (GAD-7) is a self-report measure of anxiety comprising 7 items and giving 





demonstrated to have good internal consistency, reliability and factorial validity (Löwe 
et al., 2008). For the GAD-7 scores of 5, 10 and 15 are taken as cut-offs for mild, 
moderate severe anxiety respectively. 
 
Ethical Considerations 
Ethical approval was obtained from the National Research Ethics Service 
(NRES), the Health Research Authority (HRA) and Bath University’s Psychology 
Research Ethics Committee.  
 
Analysis  
 Statistical analysis was conducted in IBM SPSS. Demographic and descriptive 
data were analysed to compare groups using t-tests and Chi Square tests.  
 
Results 
Data from a total of 82 participants were used in the analysis (IA group n = 54, 
CKD group n = 28). Data from two individuals were completely discarded due to the 
quantity of missing items and data from one individual was discarded due to incorrect 
completion of the questionnaire. Missing data for either one or two items per measure 
were imputed using the mode response from that individual on that particular measure. 
When n > 2 for missing items in a measure this response was discarded. For the 
primary analysis IA group n = 53 due to one individual completing all questionnaires 
except for MD. 
 
Group Characteristics 
 Table 1 shows demographic information for the two groups. A t-test revealed 
that participants were significantly older in the IA group, t(79) = -2.84, p < 0.01. Chi-
square tests revealed a significant association between gender and group (X2(1) = 5.85, 
p < 0.025) with proportionately fewer men in the CKD group, and employment status 





group unemployed. This may link with the IA group being older and therefore more 
individuals in retirement age.  
Table 1 
Demographic characteristics of the participants 
Demographic Characteristic  IA Group 
n = 54 
CKD Group 
n = 28 
Age (years) 
   Mean (sd) 






   Female 








   White British 
   White Welsh 
   White Irish 
   White Scottish 
   White Other 
   Mixed White and Asian 



















   Employed 









   Primary School 
   City and Guilds 
   G.C.S.E.s 
   A levels 
   University Degree 
   Master’s Degree 
   PhD 





















   Married/Civil Partnership 
   Single 
   Divorced/separated 











Other physical health conditions 
   Heart Condition 
   Respiratory Condition 













   Inflammatory/Autoimmune  
   Kidney Disease 









Current or historic mental health 
condition 
   Anxiety 
   Depression 
   Psychosis 
   Bipolar Disorder 
   OCD 

















*employed includes self-employed, full and part-time, unemployed includes student, seeking work, 
in receipt of benefits, retired and volunteer status  
 
Table 2 
Diagnoses and symptoms of CKD group 
 Number of participants  
n = 28 
Diagnosis  
    Diabetic Nephropathy 
    Hypertensive Nephropathy 
    Renovascular Disease 
    Glomerulonephritis 
    Polycistic Kidney Disease  
    Undiagnosed Cause 










   Tiredness/Sleepiness 
    Lacking Energy 
    Itchiness 
    Cramps 








Independent samples t-tests found a significant difference between groups in 
terms of self-rated severity of symptoms, t(80) = -2.12, p < 0.05, with the IA group 
scoring higher (M = 3.17, SD = 0.82) than CKD (M = 2.75, SD = 0.89). There was no 
significant difference in how burdensome the two groups found their treatment regime, 
t(80) = 0.04, p = 0.965.  See Tables 2 and 3 for information on each of the group’s 
diagnoses and symptoms. Eighty percent or more of the IA group experienced each of 
the listed common symptoms, whereas the number of individuals experiencing the 





rated severity, this suggests that the CKD group experienced less symptomology than 
that IA group. 
 
Table 3 
Diagnoses and Symptoms of IA group 
 Number of participants  
n = 54  
Diagnosis  
    Psoriatic Arthritis 
    Rheumatoid Arthritis 






   Joint Pain 
    Joint Swelling 
    Joint Stiffness 







Table 4 summarises the means, standard deviations and comparisons between 
the two groups for all target measures. A mean sensory pain and affective pain score 
was created for each participant so that the two pain scales, which had different 
maximum summed totals, were comparable. Individuals in the IA group reported 
higher levels of sensory pain than those in the CKD group and this difference was 
statistically significant t(73)= -3.58, p < 0.001. There was no statistically significant 
difference between the two groups for affective pain t(73) = -1.66, p = 0.101.  
 
Table 4 
Summary of target measures and comparisons  





Mental defeat 19.57 (25.36) 26.79 (26.54) 1.20 
Catastrophising 36.38 (18.91) 42.71 (16.02) 1.63 
Anxiety 4.51 (5.18) 7.32 (6.23) 2.04* 
Depression 6.35 (6.56) 9.07 (6.23) 1.79 
Health Anxiety  13.25 (7.32) 20.29 (8.63) 3.82** 





Fear of Disease Progression 31.25 (11.74) 41.64 (10.85) 3.89** 
Sensory Pain (mean score) 1.23 (0.75) 0.63 (0.62) -3.58** 
Affective Pain (mean score) 0.97 (0.84) 0.61 (0.88) -1.66 
*indicates significance level p< 0.05, **indicates significance level p< 0.01 
Individuals in the CKD group had significantly higher levels of anxiety t(47.09) 
= 2.04, p<0.05 (equal variance not assumed; Levene’s F(79) = 4.217, p < 0.05), health 
anxiety t(77) = 3.82, p < 0.01 and fear of disease progression t(79) = 3.89, p < 0.01, 
than the IA group. The CKD group also had higher levels of depression, and disability 
however these were not statistically significant (depression t(77) = 1.79, p = 0.078 and 
disability  t(77) = 1.62, p = 0.12).  
T-tests with gender as the grouping variable for the IA group revealed a 
significant difference for Fear of Disease Progression only, t(50)= -2.69, p < 0.05 with 
females scoring significantly higher (M= 34.26, SD = 11.82) higher than males (M= 
25.5, SD= 9.87). All other variables were not significantly different between the 
genders in this group (see Table 5).  
 
Primary Analysis 
A 2x2 mixed model ANOVA with group (IA or CKD) as the grouping factor 
and scale type (MD or catastrophising) as the within-subjects factors found a main 
effect of scale, F(1,79) = 54.8, p < 0.001. The main effect of group was not significant 
F(1,79) = 2.1, p > 0.05), nor was the interaction significant F(1,79) = 54.8, p < 0.05. 
Table 5 
IA group gender differences on key variables 





Mental defeat 16.89 (26.01) 21.32 (25.57) -0.59 
Catastrophising 33.95 (21.40) 37.53 (17.87) -0.65 
Anxiety 3.67 (5.40) 5.09 (5.10) -0.94 
Depression 6.18 (6.98) 6.44 (6.44) -0.14 
Health Anxiety  10.79 (6.89) 14.67 (7.29) -1.89 
Disability 12.63 (11.35) 16.84 (10.91) -1.31 
Fear of Disease Progression 25.50 (9.87) 34.26 (11.82) -2.67* 
Sensory Pain (mean score) 1.16 (0.96) 1.31 (0.64) -0.61 
Affective Pain (mean score) 0.90 (0.96) 1.02 (0.80) -0.46 






 Mental Defeat 
The CKD group reported higher levels of MD (M= 26.79, SD= 26.54), than the 
IA group (M= 19.57, SD= 25.36 however this difference was not statistically 
significant, t(79) = 1.20, p= 0.234. Both of the IA and CKD groups had significantly 
higher levels of MD compared with a sample of community, healthy controls (M = 7.2, 
SD = 9.3), t(114)= 3.99, p< 0.01 and t(99)= 4.91, p< 0.01, respectively.  (Carrick, 
Salkovskis, & Griffith, 2016).   
A correlational analysis revealed a Pearson’s  r correlation coefficient for MD 
and depression of 0.74 (p < 0.01) and for MD and anxiety of 0.68 (p < 0.01), 
confirming that the both anxiety and depression are correlated to the MD construct.  
 
Catastrophising 
The CKD group reported higher levels of catastrophising (M= 42.71, SD= 
16.02, than the IA group (M= 36.38, SD= 18.91) however this difference was not 
statistically significant, t(80) = 1.63, p= 0.12. 
 
Secondary Analysis  
A psychological distress score was created for each participant by summing 
their total PHQ-9 and GAD-7 scores. A stepwise multiple regression was conducted 
with psychological distress as the dependent variable and MD, catastrophising, age, 
sensory pain, affective pain, health anxiety and disability as independent variables. 
Several assumptions required for analysis were tested prior to conducting the 
regressions. All of the IVs in the regressions had a Pearson’s r correlation coefficient of 
below 0.7 except from the two types pain scores (r = 0.82). All of the IVs were 
correlated to the DV (r > 0.3) except for age (r = 0.21) and there were no outliers on 
the predictor variables or outcome variable (Cook’s Distance maximum value < 1 for 
all). Results showed that MD, health anxiety, disability and catastrophizing were all 
associated with psychological distress and all contributed significantly to the model, 
F(1, 67)= 4.44, p< 0.05, R2 = 0.72 (see Table 6). Taken together, these four predictors 
accounted for 72% of the variance in psychological distress scores. MD was 





2a) MD is associated with psychological distress can be accepted and the null 
hypothesis rejected. Entering MD into the model accounted for 55% of the variation in  
Table 6 
Stepwise Multiple Regression analysis with psychological distress in adults with LTCs 
as the dependent variable 





MD 0.55 0.55 0.12 0.26 2.49 0.015 
Health Anxiety 0.65 0.10 0.41 0.29 3.55 0.001 
Disability 0.70 0.05 0.26 0.25 2.56 0.013 
Catastrophising 0.72 0.02 0.07 0.03 2.11 0.039 
Note: Excluded variables; Sensory Pain, Affective Pain and Age 
 
psychological distress scores. Adding health anxiety to the model accounted for 
a further 10% of variation in scores, with disability adding 5% and catastrophising 
another 2%. The other variables, sensory pain, affective pain and age were removed from 
the model as they did not contribute significantly. 
A second stepwise multiple regression was conducted with fear of disease 
progression as the dependent variable and MD, catastrophising, age, sensory pain, 
affective pain, health anxiety and disability as independent variables. Results showed 
that health anxiety, age and MD all contributed significantly to the model, F(1,68) = 
11.49, p< 0.1, R2= 0.68 (see Table 7). Taken together, these three predictors accounted 
for 68% of the variance in fear of disease progression scores. Health anxiety was 
significantly associated with fear of disease progression, p< 0.01, therefore the 
hypothesis 2b) health anxiety is associated with fear of disease progression can be 
accepted and the null hypothesis rejected. Health anxiety accounted for 55% of the 
variation in Fear of Disease Progression scores. Adding age to the model accounted for 
an additional 8% of variation and adding MD accounted for a further 6%. The other 
variables, catastrophising, sensory pain, affective pain and age were removed from the 









Stepwise Multiple Regression analysis with fear of disease progression in adults with 
LTCs as the dependent variable  







0.55 0.55 0.77 0.52 6.09 <0.001 
Age 0.63 0.08 -0.23 -0.25 -3.44 0.001 
MD  0.68 0.06 0.14 0.29 3.39 0.001 
Note: Excluded variables; catastrophising, sensory pain, affective pain and age 
 
Discussion 
This research aimed to explore whether MD occurs in specific LTCs (IA and 
CKD) and if so whether it differs between the two conditions. Findings indicate that 
MD does occur in individuals with both IA and CKD at levels higher than that of a 
healthy sample, but that there is no significant difference between the two conditions.   
The primary hypothesis, there will be higher levels of MD in arthritic patients than 
renal but no difference across the groups in catastrophising, can be rejected and the null 
hypothesis accepted. 
Catastrophising occurred equally in both groups. Having a LTC with an 
unpredictable and uncertain prognosis may contribute to negative beliefs about the 
future of the illness itself and its effect on an individual, as well as negative beliefs 
about the self and identity.  
Previous research has found a link between chronic pain and MD therefore it 
was hypothesised that there would be more MD in the IA group, due to the presence of 
more painful symptomology. The results presented here do not support this and suggest 
that the experience of sensory pain is not necessary for MD to be present. Additionally, 
pain was removed from both regression models, suggesting that it was not associated 





had median sensory and affective pain scores (12 and 3 respectively) comparable to 
those of RA patients reported in the literature (10 and 2), suggesting that the level of 
pain in this group was not unusually low (Davis et al., 2014).  The results suggest that 
having a LTC in itself may put you at risk for having higher levels of MD than healthy 
controls and the type of condition/symptomology (e.g. higher pain) may be less 
important.  
An alternative explanation for the non-significant findings in relation to 
differences in MD across the two groups may be that medically unexplained pain 
(chronic pain) is experienced differently to medically explained pain e.g. in IA. A 
medical explanation for the pain in IA may mean that whilst unpleasant and 
unpredictable, the person appraises the experience less in relation to a negative view of 
themselves and therefore experiences less MD. 
Overall the CKD group scored higher on many psychological variables, 
including MD, catastrophising and health anxiety, than the IA group. This may be 
accounted for by the younger age of the CKD group or by the difference in disease 
prognosis. It may be that younger individuals interpret their LTC as having a more 
negative effect on their life and their identity. In a sample of individuals with Chronic 
Obstructive Pulmonary Disease (COPD) those over the age of 60 were significantly 
less likely to be depressed or anxious than those under 60 (Cleland, Lee, & Hall, 2007). 
Although the prognosis of both IA and CKD can be viewed as similar (e.g. uncertain, 
often progressive deterioration) there are differences in the severity of the end stage of 
each disease. In CKD end stage the patient is reliant on medical procedures (e.g. 
dialysis/transplant) to stay alive, whereas in end stage IA individuals will have lost 
function of joints (Simmons, 2013). Whilst the prognosis of loss of mobility in IA will 
surely come with anxiety and distress, this is something we all inevitably face as we get 
older. It seems reasonable that the threat of dialysis/transplant or early mortality could 
warrant higher levels of anxiety about the condition and the future in the CKD group.  
 The secondary analyses found that MD is strongly associated with 
psychological distress, accounting for over half of the variation in psychological 
distress scores. This fits with previous research on MD in chronic pain and MS (Brown 
et al., 2017; Tang et al., 2010).  Similarly, health anxiety accounted for over half of the 
variation in fear of disease progression scores. This fits with previous research 





overestimated negative beliefs about their illness it follows that their predictions of the 
future of their illness will also be negative and vice versa.  
 
Clinical Implications 
This study provides evidence that MD occurs across LTCs where painful 
symptoms are present (IA) and also in conditions where there is less pain and 
symptomology. Whilst the link between the experience of chronic pain, MD and 
catastrophising has been established, this research highlights that pain in itself is not 
necessary for the presence of MD. This is important clinically because when MD is 
present it is strongly associated with psychological distress (anxiety and depression). 
This information is helpful for medical professionals to be aware of so that individuals 
with MD might be identified and offered targeted support and psychological 
intervention. 
 The findings that MD followed by health anxiety are most strongly associated 
with psychological distress may not be surprising to clinicians working with these 
LTCs. However, it is important to be able to discriminate different cognitive processes 
contributing towards psychological reactions to living with a LTC so that the correct 
model can be used in the intervention. 
 It is also worth noting that in the sample studies here, both groups scored in the 
moderate range on the PHQ-9 and GAD-7 and only the CKD group mean just reached 
the cut-off (9) on the PHQ-9 often used to suggest the presence of clinical depression. 
This is likely to be representative of the wider population being studied, as you would 
not necessarily expect a group of individuals with a chronic illness to be 
psychologically unwell and therefore score in the severe ranges of these measures. This 
is important clinically as whilst the presence of MD may correlate to increased levels of 
psychological distress, this psychological distress is not at a severe level, which 
suggests less intensive interventions may be adequate. It may be that in the groups 
studied here, the levels of MD were not high enough to contribute to significant 
psychological distress, or it may be that psychological distress levels would not have 
changed qualitatively even with raised MD. In previous research, chronic pain patients 
scored higher on MD (M= 36.2 compared with IA M= 19.57 and CKD M= 26.79) 
however still scored within the ‘mild’ category on mood measures used (Tang et al., 
2007). This suggests that whilst MD is associated with psychological distress, it alone 





one psychological construct amongst many which contributes to these more global 
presentations.  
Individuals with CKD may have higher levels of general anxiety, health anxiety 
and fear of disease progression than those with IA. Health anxiety is associated with 
fear of disease progression and this could potentially manifest itself in reassurance 
seeking, self-management issues and treatment seeking such as increased medical 
utilisation (Fergus, Griggs, Cunningham, & Kelley, 2017), making it an area that 
warrants further research. Older adults are reported to have significantly higher levels 
of health anxiety than younger adults (Fergus et al., 2017) yet the CKD group reported 
here were of a younger age than the IA group. Health anxiety in individuals with LTCs 
may be moderated by factors other than age, such as severity of symptoms or 
uncertainty of disease prognosis.  
 
Limitations 
Whilst the total sample size was adequate based on the a priori power calculation 
for the ANOVA, the study was underpowered for the secondary regression analyses 
which would have ideally had 60 participants in each group.  Recruitment difficulties for 
the CKD group may in part have been due to the exclusion criteria. Individuals with CKD 
that have a GFR of less than 30 but are not yet in renal failure may be less present in 
online support groups (that the social media recruitment targeted) and also less frequent 
visitors to the renal clinics.  However, the recruitment difficulties in this group do not 
reflect a population without need for support or treatment as those with CKD had higher 
levels of mental health difficulties. It could be that only this subset of those with early 
stage CKD have raised levels of distress, and those individuals tend to seek 
treatment/support more than others and were therefore captured in this research. 
Alternatively, it may be that the small sample of individuals here with CKD are reflective 
of the wider population.  
A further limitation of this research is the difference in group characteristics 
including age and gender, which potentially confound the comparisons. The CKD 
group were almost entirely female (89%) which raises the question of whether between 
group differences reflect only gender differences. An analysis controlling for gender 
was conducted to check for this. In the IA group, where gender was more equally 





females for fear of disease progression, where females scored higher. This finding goes 
some way to support the conclusion that the group differences for all other variables 
observed here do not just reflection gender differences. Gender was picked as a 
covariate because the between group differences were most apparent for this variable, 
however additional analysis including other variables e.g. unemployment as covariates 
could have been run and may have strengthened the analysis.  
 
Future Research 
This study offers only an initial exploration of MD in these two conditions, 
therefore further research involving larger numbers and longitudinal studies to explore 
change over time is warranted.  
Whilst this study indicates the presence of MD and other psychological 
complications in two LTCs, further research is needed to determine whether the 
influence of factors associated with different stages of LTCs and to explore whether 
MD is common to LTCs more widely. 
In addition to exploring whether MD occurs across a variety of LTCs, it would 
be interesting to compare expected medical prognosis with the patient’s expected future 
prognosis and explore any associations between fear of disease progression and other 
psychological factors.  
 
Conclusion  
 Through this initial exploration it has been identified that MD occurs in 
individuals with two LTCs above the level of a healthy control and that specific 
symptomology may be less of an indicator for MD than initially thought. In order to 
target individuals with the most need for intervention, we need to explore whether there 
are certain types of LTCs where MD is more likely e.g. those with a highly uncertain 
prognosis, or whether there are in fact a certain demographic of individuals who are 
more vulnerable to experiencing it.  
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Executive Summary of Main Research Project: Mental Defeat in Long 
Term Health Conditions  
 
Health Psychology research has recently explored the role of Mental Defeat (MD) as a 
process contributing towards psychological distress in certain LTCs, including chronic 
pain. MD has been defined as the perceived loss of autonomy in the face of 
uncontrollable traumatic events, resulting in the person giving up efforts to retain 
identity and self-will. MD has been likened to a type of catastrophising focused on the 
self, the person’s life and their identity. In contrast, general catastrophising is focused 
on what the pain/illness means for the person in terms of their health. In the chronic 
pain literature MD raised levels of MD have been indicated as an important mediator of 
distress and disability and as a predictor for heightened suicide risk. So far there is 
limited research on MD outside of chronic pain. If mental defeat does occur in other 
LTCs it may be a cognitive process that affects treatment seeking, suicidality, symptom 
severity, and levels of distress, making it a useful area for research to both improve the 
support available for patients and minimise unnecessary medical visits. This study 
aimed to explore whether mental defeat (MD) occurs in two long term health 
conditions (LTCs) with differing symptomology and pain levels; chronic kidney 
disease and (CKD) and inflammatory arthritis (IA). 
The primary hypothesis was split into two parts 1a) There will be a difference in 
levels of MD between renal and arthritic patients (due to the difference in symptoms 
and treatment) and 1b) There will be no difference in levels of general catastrophizing 
(due to the chronic yet uncertain nature of both diseases). The secondary hypotheses 
were 2a) Psychological distress will be associated with mental defeat and 2b) Fear of 
disease progression will be associated with health anxiety.  
This study used a cross sectional questionnaire design with two groups IA and 
CKD. Participants from both groups were recruited from NHS outpatient clinics in the 
local area and online via social media adverts linked to two charities supporting the 
conditions respectively. 28 participants were recruited in the CKD group and 54 
participants were recruited in the IA group. Participants completed a battery of 
questionnaires about their experience of, and their beliefs and feelings about their 
health condition. A mixed model ANOVA and stepwise regressions were conducted to 





MD occurred in individuals with both IA and CKD at levels higher than that of 
a healthy sample, but that was no significant difference between the two conditions. 
The results presented here suggest that the experience of sensory pain is not necessary 
for MD to be present. Catastrophising occurred equally in both groups. Having a LTC 
with an unpredictable and uncertain prognosis may contribute to negative beliefs about 
the future of the illness itself and its effect on an individual, as well as negative beliefs 
about the self and identity.  
A stepwise regression revealed that MD, health anxiety, disability and 
catastrophising were all associated with psychological distress. A second regression 
revealed that MD, age, and health anxiety predict fear of disease progression. Pain was 
removed from both regression models, suggesting that it was not associated with 
psychological distress or fear of disease progression in either group. 
Overall the CKD group scored higher on many psychological variables, 
including MD, catastrophising and health anxiety, than the IA group. This may be 
accounted for by the younger age of the CKD group or by the difference in disease 
prognosis. There were significant differences in gender between the two groups, with 
the CKD group being 89% female. This difference, along with numbers recruited and 
age differences between the two groups is a limitation of this study. 
Through this initial exploration it has been identified that MD occurs in 
individuals with two LTCs above the level of a healthy control and that specific 
symptomology may be less of an indicator for MD than initially thought. In order to 
target individuals with the most need for intervention, we need to explore whether there 
are certain types of LTCs where MD is more likely e.g. those with a highly uncertain 
prognosis, or whether there are in fact a certain demographic of individuals who are 











Main Research Project: Mental Defeat in Long Term Conditions 
The courses’ ethos and specialist interest in Health Psychology helped me to 
pick this area for my main research project due to the expertise already held amongst 
course staff and previous trainees. The process of designing my research was very 
difficult as I had very limited research experience prior to training, but I was very lucky 
to have good support from my supervisors in this process. I learnt a lot during this 
process and quickly realised that my ‘research idea’ was extremely vague and I learnt 
how to move from a vague idea into a concrete research question and hypotheses with a 
study design to match this. Writing the research proposal and presenting it to the 
research team for approval helped to ensure that the research design was sound from an 
early stage. Something I will always remember form this time is the advice that “good 
research shouldn’t aim to change the world but instead just aim to answer one, new 
question.” 
Gaining NHS ethical approval is something that I will probably always recall as 
very difficult due to the long and unknown process. However, it is certainly something 
that I am pleased to have experienced on training as I now feel much better equipped to 
complete this again when I am involved in research in my post-qualification practice. It 
was very helpful to have advice from the year above on the IRAS process. I didn’t 
realise until completing the IRAS form how much detail of your research you had to 
have set in stone, e.g. measures etc. This came from a place of naivety and inexperience 
with this process, but I now see that having all of the details of the research worked out 
before ethical approval is of course required so that the panel can make an informed 
decision. My study only needed proportionate review as opposed to a full Research 
Ethics Committee (REC) review so once I had submitted my IRAS form I was lucky 
enough to get approval quickly after a few amendments. With NHS ethical approval 
granted, the University ethical approval and local R&D (via HRA) was also granted 
quickly.  
 I started recruiting for the project in late summer last year. I expected this 
process to be slightly smoother than it was. I think that I was optimistic…despite the 
helpful warnings from others that recruitment is always more difficult than you expect. 
I struggled to recruit the numbers I had predicted for my CKD group for two main 





the clinics and my target population, during the recruitment period it transpired that 
individuals who met my inclusion criteria were not as common in these clinics as 
predicted. Secondly, due to high staff turnover and associated stress levels and an 
increase in agency staff, staff who had agreed to help out with recruitment were no 
longer able to do so.  
 Both of my internal supervisors who have experience of research/clinical work 
in health psychology really helped me to apply theoretical knowledge to my research, 
both in the design stage but also when writing up results. I was able to consult with 
individuals with PPE to pilot my questionnaire and I was also able to consult with a 
Consultant from each LTC to help me narrow my inclusion/exclusion criteria. The 
Consultant from Rheumatology helped me to recruit and was key to ensuring I got 
good number in this group. 
 The results of my main research project are not quite what we predicted, 
however, just the results are still clinically useful and interesting. My project explores 
mental defeat in two long term conditions and there are not the hypothesised 
differences in levels of mental defeat across the two conditions. My findings suggest 
that just having a long term condition itself may be the important factor which makes 
you vulnerable to the psychological complications associated with long term 
conditions, as opposed to the types of symptoms you experience. The knowledge I have 
gained from my project is helping me in my current placement as I am working in 
paediatric health with the renal team and one of the conditions in my research was 
chronic kidney disease. I had hypothesised that in the early stages of CKD individuals 
would experience less psychological distress and MD but this is not the case, and my 
developing understanding of the condition and the uncertainty of the prognosis fits with 
this. 
 
Service Improvement Project: An evaluation of the Current Screening Tools used 
in the Offender Personality Disorder (OPD) Pathway 
When I heard about this SIP with the Pathfinder team I was immediately 
interested as it combined two areas I had interest/experience in; Forensics and 
Personality Disorder. I liked the fact that it was a mixture of quantitative analysis to 
look at the numbers of people screened in and out of the service using a national tool, 
and then a qualitative analysis to find out about the experience of an additional 





its nature led by the service’s need, there was less of a process of development in this 
project than the others.  
This is the project which I was able to get going with quite quickly in the first 
year. I applied for ethical approval from the university and from the local R&D team 
and this was granted without any problems. I had to wait to schedule the focus-group 
interview for the team away day but prior to this I could get on with the quantitative 
analysis myself, which involved coding a spreadsheet of data that is routinely kept by 
the service to look at the numbers of false positives and false negatives identified 
through using the screening tool. In terms of recruiting for the focus-group, I sent out 
information sheets and consent forms prior to the day so that people had the chance to 
consider their involvement. I had over six people consent to participating in the focus-
group but on the day only five took part, one of whom contributed very minimally.  
Running the focus group itself was a good learning experience. I felt nervous 
attending a team away day and facilitating discussion for a group of people I hadn’t met 
before however it went well and I felt this experience boosted my confidence. 
Analysing the focus-group was a steep learning curve as I had never undertaken 
qualitative research of thematic analysis before. My field supervisor let me borrow a 
book which he had used when doing his first analysis and I found this very helpful as it 
broke the process into stages and spoke specifically to analysing focus-groups, as 
opposed to individual interviews. This evidenced framework definitely helped me to 
complete this piece of work. As I progressed through identifying my themes and 
subthemes I found it very helpful to have feedback from both my internal and external 
supervisors on how they might categorise, name and explain the themes I had initially 
identified.  
The quantitative results of the project suggested that the screening tool was 
more accurate than the team had expected it to be, with it only ‘missing’ a very small 
number of cases. The qualitative analysis suggested that the additional screening 
process was deemed useful by staff but that there needed to be boundaries around the 
spacing of the interviews, the length of the interviews and the amount of information 
shared to ensure the process was time efficient in the long run. I fed these results back 
to the team at their next away day and engaged in a small discussion with the manager 
and the team members. This is something that stands out for me as an experience which 
reminded me of the importance of doing useful/applicable research, rather than 





were going to use the results to inform their practice, specifically they planned to 
streamline their screening process to only discuss positive results from the screen as the 
tool appears to be over-inclusive.  
 
Critical Review of the Literature: How effective are medium-term CBT 
interventions in treating BPD? 
I selected this area for my literature review due to my already mentioned 
interest in borderline personality disorder. This stemmed from experience working with 
individuals going through DBT, noticing how all-encompassing the illness can be but 
also noticing how much of a positive impact the therapy had. Having worked in 
secondary mental health services I also knew that access to this comprehensive therapy 
was limited and that there are now shorter interventions being offered for individuals 
with BPD. In my first placement, I was able to co-facilitate the STEPPS group, a 20-
week programme. When I met with my internal supervisor to discuss literature review 
ideas and this idea came up it seemed to fit with my experience and my interests very 
well. 
With the question set, I moved on to defining my search terms and 
inclusion/exclusion criteria for the review. I found this difficult as I had not engaged in 
a systematic review before and had limited experience of using the databases and their 
advanced search functions. When I had a rough set of search terms I met with the 
librarian who was extremely helpful in helping me to adjust my terms to capture what I 
needed across the different databases. Unfortunately, my searches returned a large 
volume of abstracts (almost 3000) due to the fact that I needed to search broadly for 
cognitive behavioural type interventions and then narrow down to the ‘medium-length’ 
by hand, as there were no search terms that could easily quantify this. The process of 
reviewing the abstracts and discarding the unnecessary ones was very time consuming, 
especially as many abstracts didn’t define the length of the intervention so I had to 
review the full text.  
 Initially I included all intervention studies, not just RCTs, as I was unsure that 
there would be enough RCTs to include. However, myself and my supervisors were 
pleasantly surprised to find that there were enough. With the decision to only include 
RCTs came the decision to complete a meta-analysis alongside the systematic review. 
This is not something I have experience of so I had to do a lot of reading and consult 





very challenging as some of the concepts of advanced statistics can be difficult to get 
your head around. However, through this process I have learnt a huge amount and I am 
glad that I was able to add an extra layer of quantitative analysis to my review. I chose 
to keep my review focused on BPD outcome measures and risk outcomes, although 
there are many more outcome measures used and reported in the BPD literature. I did 
this so that the review is easy to read and digest, and so that clear conclusions can be 
drawn, instead of presenting. I have received very helpful supervision from both my 
internal and external supervisor, especially regarding the write-up of my review. 
Advice from a statistician, alongside reading, helped me to decide which method of 
meta-analysis to use.  
 The results of my review are clinically useful as they suggest that medium term 
interventions are effective in reducing BPD symptoms measured by BPD outcome 
measures. At a time when there is pressure on the NHS to provide more for less this 
information can help to inform decisions on whether to provide shorter interventions. 
The results of the review were less conclusive about the impact of medium term 
interventions on risk behaviours as only a small number of RCTs reported significant 
improvements in the intervention group. This too is clinically very useful. The National 
Institute of Health Research (NIHR) have been in contact with me to ask for the results 
of my review, after seeing my protocol published online.  
 
Case Studies 
 For me, the process of writing the first case study felt extremely different from 
writing the remaining four. I remember looking up examples and feeling very unsure 
about what to include in my first case study and how to write up my work. I was in a 
position on my first placement where I had limited cases therefore the decision of 
which case to write up was made a lot easier. Receiving feedback on my first case 
study and then making the necessary amendments to get it to pass felt like a relatively 
large milestone. I certainly learnt a lot about my preferred style of writing up cases and 
what is expected from a course/academic point of view when writing case studies, as 
each case study that followed felt a little bit easier. I suppose the process of picking an 
individual and writing it up became more familiar and this allowed for the process to be 
more reflective and allow for thinking space on each client, instead of worrying about 





placements, the individual I chose to write-up gave their consent without any 
difficulties.  
 Writing up the case studies throughout the placements also helped to 
consolidate my theoretical knowledge of each presenting problem, both the model 
specific knowledge and also the crossover in the cognitive theory for example.  
 My C1 and C3 case studies were single case experimental designs and these felt 
more difficult just in terms of making sure I collected enough baseline measures and 
idiosyncratic measures. Learning about the requirements for SCEDs made sense in 
teaching however the reality of trying to collect good quality outcome measures 
regularly can be quite different. Whilst it is good practice and many services ‘should’ 
be doing it routinely, my experience is that many of the services I have worked in do 
not. I think that collecting measures for the purpose of the case studies helped me to 
consolidate this into my practice so that going forward I will aim to regularly collect 
outcome measures from my clients.  
 Receiving written feedback from my supervisors on my written case studies 
provided an interesting contrast/difference in communication methods, as we had been 
discussing the case verbally in supervision throughout the placement. It was also 
interesting to compare the feedback from my placement supervisors whose 
recommendations often centred around aspects of the case context or intervention, as 
opposed to feedback from my academic marker, which often focused more on theory 
and literature. Both types of expertise helped me to create five case studies which I am 
proud of and I feel reflect a range of the CBT work I have engaged with over the course 
of training.  
 Looking forward to my post-qualification work, I would like to consider writing 
up interesting case studies for publication, when this feels possible and useful. I 
recognise that time to engage in research and academia can be very hard to find with a 
demanding caseload, so even if I am unable to write up a case that I would like perhaps 
sharing interesting case work amongst peers and the team would help to spread 
knowledge and good practice. This could be as formal (e.g. monthly case study 
meetings with an allocated presenter) or informal (peer discussion) as required.  
 I think time will be the biggest barrier to me engaging in research projects in 
my role once I’m qualified. Whilst this could make it easy to take a step back from 
research in my next job, I think doing this would mean losing the huge amount of 





very beneficial to ‘use it not lose it’. As a first step I think planning to actively find 
opportunities in the service for audit or consultancy within the first year of my role 
would help me to stay active in the field of research whilst managing the transition to 
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Bath. There have been some changes over the three years (especially in the admin 
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List of other outcome measures used by each study 
 
Author Name (Year) Outcome Measures uses  
Adreasson et al. (2016) Hamilton Depression Rating Scale (HDRS) 
Beck Depression Inventory II (BDI-III) 
Beck Hopelessness Scale (BHS) 
Rosenberg Self-Esteem Scale (RSE) 
Blum et al. (2008) Clinical Global Impression- Self-Rated (CGI-SR)  
Glasgow Anxiety Scale (GAS) 
Beck Depression (BDI) 
Symptom Check-list 90 revised (SCL-90-R) 
Barrett Impulsiveness Scale (BIS-II) 
Social Adjustment Scale (SAS) 
Bos et al. (2010) Symptom Check-list 90 (SCL-90)  
WHO Quality of Life Assessment BREF (WHOQOL-
BREF) 
Farrell et al. (2009) Symptom Check-list 90 (SCL-90)  
Global Assessment of Function Scale (GAFS)  
Gratz et al. (2006) Difficulties in Emotion Regulation Scale (DERS)  
Acceptance and Action Questionnaire (AAQ) 
Depression Anxiety Stress Scale (DASS) 
Koons et al. (2001) Beck Depression (BDI) 
Hamilton Depression Rating Scale (HDRS) 
Dissociative Experiences Scale (DES)  
Hamilton Anxiety Rating Scale (HARS) 
Spielberger Anger Expression Scale (SAES)  
Health care utilisation 
Moreton et al. (2012) Depression Anxiety Stress Scale (DASS) 
Acceptance and Action Questionnaire (AAQ) 
Difficulties in Emotion Regulation Scale (DERS 
Five Factor Mindfulness Questionnaire (FFMQ)  
The Affective Control Scale (ACS) 
McMain et al. (2017) State-Trait Anger Expression Inventory (STAXI) 
Distress Tolerance Scale (DTS) 
Symptom Check-list 90 (SCL-90) 
Beck Depression Inventory II (BDI-III) 
Social Adjustment Scale self-report (SAS-SR) 
Difficulties in Emotion Regulation Scale (DERS 
Health care utilisation 
Paacual et al. (2015) Hamilton Anxiety Rating Scale (HARS) 
Barrett Impulsiveness Scale (BIS-II 
Functional Assessment Scale Test (FAST) 
Montgomery-Asberg Depression Rating Scale (MADRS 
Soler et al. (2009) Symptom Check-list 90 (SCL-90)  
Hamilton Depression Rating Scale (HDRS) 
Hamilton Anxiety Rating Scale (HARS) 
Brief Psychiatric Rating Scale (BPRS) 
Barratt Inventory (BI) 










Consult a current issue of the Journal for style and format. The text should be in 
double-spacing with broad margins. Review articles/meta-analyses, clinical overview 
articles and original articles all follow the same concept: 
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city and country of location. Please also include a running title with a maximum of 50 
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Interview Schedule for Focus-group (6-8 participants) and suggested prompts  
 
1. What effect do you think the addition of the screening interviews (to the 
OASys) tool) has had on the screening process as a whole? 
 
2. What role does the OASys tool have in the screening process? 
 
3. What has been your experience of the screening interviews so far? 
 
4. Are there ways in which you think the screening interviews are 
beneficial/helpful? 
- For OPD clinicians? 
- For service users? 
- For probation officers? 
 
5. What, if anything, would you change about the current screening process? 
- Is there anything particularly difficult or unhelpful that you have 
experienced? 
 
6. How time effective do you think the current screening process is? 
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1.       Please	 confirm	 that	 the	 data	 will	 be	 stored	 in	 compliance	 with	 the	 University’s	
Research	Data	Policy.		
2.       Please	verify	that	warnings	will	be	made	to	avoid	using	offenders’	names	during	the	
interviews	 as	 suggested	 in	 the	 ethics	 email.		 This	 should	 also	 be	 mentioned	 in	 the	
information	sheet.	
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Article Types 
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occasion with the abbreviated version in brackets, and thereafter in the abbreviated 
version. For example, ‘...women remanded for pre-sentence reports (PSRs)...’. If, say, 





Capitals: ‘Emphasis capitals’ should be avoided. Do not capitalise ‘police officer’, 
‘probation service’, criminal justice system, etc. 
Diagrams and Tables: These should be used sparingly. Their location in the text should 
be indicated clearly in the typescript. 
Title, Keywords and Abstracts 
Titles and Sub-Headings: The suggested title should appear on the first page of the 
manuscript. Sub-headings are encouraged to create a more readable, accessible and 
logically developed paper. Please use normal sentence case type. 
Abstract: The submission should be preceded by an abstract of 50-100 words indicating 
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images etc) alongside the full-text of the article. For more information please refer to 
our guidelines on submitting supplementary files. 
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Probation Journal adheres to the SAGE Harvard reference style. View the SAGE 
Harvard guidelines to ensure your manuscript conforms to this reference style. 














Screening questions for CKD Group 
 
We would like you to answer a few questions to check that you meet the criteria for 
participating in this study. Please circle the response to each question: 
 
1.     Are you aged under 18 years?  Yes /  No 
2.     Do you consider yourself to be NOT fluent in English?   Yes /  No 
6.     Do you have a GFR score of 30 or above?                         Yes /  No 
7. Have you had a kidney transplant?  Yes /  No 
8. Are you currently receiving dialysis?  Yes /  No 
 
If you have answered Yes for any of the questions above, you unfortunately do not meet 
the criteria for the study. Please do not continue with the questionnaire. We would like 
to take this opportunity to thank you for your interest in this study, and for your 




Screening questions for IA Group 
 
We would like you to answer a few questions to check that you meet the criteria for 
participating in this study. Please circle the response to each question: 
 
1.     Are you aged under 18 years?  Yes /  No 
2.     Do you consider yourself to NOT be fluent in English?   Yes /  No 
       
           3. Do you have a type or arthritis that is NOT Rheumatoid or Psoriatic?  Yes /No 
 
If you have answered Yes for any of the questions above, you unfortunately do not meet 
the criteria for the study. Please do not continue with the questionnaire. We would like 
to take this opportunity to thank you for your interest in this study, and for your 














Background information Questionnaire  
 
1. What gender do you identify as (please circle)?     Male / Female/Other (please 
specify____________) 
 
2. What is your age?   ………years 
 
3. What is your ethnicity? (Please tick) 
 
White  Asian 
British  Indian  
Welsh  Pakistani  
Irish  Bangladeshi  
Scottish  British  
Other   Other:  
Black Mixed  
African  White and Black Caribbean  
Caribbean  White and Black African  
British  White and Asian  
Other  Other  
Any Other (specify below)    
    
 
 
4. What is your employment status? (Please tick)  
 
Employed (full time)  Homemaker  
Employed (part time)  Student (Full time)  
Employed (self)  Student (Part time)  
Unemployed (Seeking work)  Retired  
Unemployed  Volunteer  
In receipt of benefits    
 
5. What is your highest level of Education? (Please tick)  
 No education   Primary school   City and guilds    G.C.S.E.s  
  
 ‘A’ levels    University Degree  Master’s Degree      PhD  
 Other (specify which):____________________  
 
6. What would you describe as your relationship status? (Please tick) 
 Married/civil partnership   Single  
 Divorced/separated    Widowed  
 
7. What type of kidney disease are you diagnosed with? (Please tick)* 
 
 Diabetic Nephropathy   Hypertensive Nephropathy         Renovascular 





 Glomerulonephritis     Polycystic Kidney Disease  Undiagnosed cause  
 Other 
 
8. Below are a list of commonly reported symptoms of chronic kidney disease. 
Please tick all that apply to you.* 
 Tiredness/Sleepiness  Lacking energy     Itchiness       Cramps 
  Nausea          
 
9. How would you rate the severity of your symptoms? (Please circle) 
 
1	 2	 3	 4	 5	
None	 Mild	 Moderate	 Severe	 Very	Severe	
 
11. Do you find your current treatment for your kidney disease burdensome? 
(Please circle). Burdensome is defined as difficult to carry out or taxing.  
 
1	 2	 3	 4	 5	
No	 A	little		 Moderately	 Very	 Extremely	
 
12. Do you have any other physical health conditions? Please tick all that apply to 
you. 
 










13. Do you have any current or historic mental health conditions? Please tick all 
that apply to you. 
 Anxiety        Depression    Psychosis       Bipolar Disorder  
 
 OCD               Other (please specify) ___________________________ 
 
 
Thank you for completing this information.  
  
 
On the following pages you will now be asked to complete a series of questionnaires.  
Please complete these questionnaires in relation to your kidney disease and the 
kind of physical experiences you may have because of this condition e.g. nausea, 
dizziness, high or low blood pressure.* 
 
 
NOTE: * indicates questions which had slight variations for the IA group background 
information questionnaire, e.g. asking about common types of arthritis and symptoms 
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Client consent form – Psychological Reactions to Physical Illness 
 


















securely	 and	 kept	 confidential,	 except	 in	 the	 circumstances	 where	








I	 understand	 that	 I	 have	 the	 right	 to	withdraw	 from	 the	 study	at	 any	
point	without	giving	a	reason.	I	can	request	that	my	data	be	withdrawn	
from	 the	 study	 and	 destroyed	 up	 until	 the	 point	 that	 I	 hand	 my	










Name of participant (Print)  Signature of participant  Date 
     
     
     
     


















University of Bath- Department of 
Psychology 
 
Participant Information Sheet 
 
We would like to invite you to take part in a research study.  Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others if you wish. Please ask 
us if there is anything that is not clear or if you would like more information; contact details 
are available below. Take time to decide whether or not you wish to take part. 
 
Study Title: Psychological Reactions to Physical Illness 
 
Why is the study being done? 
This study aims to find out more about people’s psychological reaction to having chronic 
health conditions (including Chronic Kidney Disease) so that treatment for any psychological 
distress associated with chronic health conditions can be improved. 
 
Do I have to take part? 
No you do not have to take part in the study. Your decision to take part in the study, or not 
take part in the study will not have any impact on the treatment you receive here at the clinic.  
 
What will I be asked to do? 
Participants will be asked to complete a pack of self-report style questionnaires about their 
beliefs and experiences relating to their condition. There are a number of questionnaires and 
we estimate that this should take most people no longer than 20-25 minutes to complete.  
 
Where and when will the study take place? 
If you decide you would like to take part in the study the questionnaires will be provided for 
you today. You are invited to complete these during your visit to the clinic and we ask that 
you return the completed questionnaire pack into the box labelled ‘Psychological Reactions 
Questionnaires’. We are happy to discuss an alternative method of completing/returning your 
questionnaire  pack if this is more convenient to you. 
 
What will happen to the information I provide? 
The information you provide will remain anonymous as you will not be asked to give your 
name or any personally identifiable information. The data from the completed set of 
questionnaires will be compared to data from participants with a different chronic health 
condition. The findings will be written up and published in an academic journal. A poster 
summary of the findings from the research will be posted in the clinic waiting room and 
online on the following website: (url tbc)  
 
Are there any advantages to taking part? 
The benefits of taking part in this study include contributing to research which improves 
understanding about the psychological impact of chronic health conditions which could 
subsequently lead to improved treatment of psychological distress in health conditions. A 
charity donation of £2 will also be made to the National Kidney Federation for every 

















Are there any disadvantages to taking part? 
We envisage that the disadvantages of taking part in this study will be minimal. Some of the 
questionnaires involve questions about sensitive topics including the impact of living with the 
CKD. Some participants may find this upsetting to think about. If you do decide to take part in 
the research and you feel distressed at any point then you can stop participating in the research 
with out giving a reason and without repercussion. If you do feel distressed and would like to 
speak to somebody then you can contact the Lead Researcher (Zoe Mawby, Clinical 
Psychologist in Training).  
 
Some links to information and support that you may find useful are listed below.  
 
What do I do next if I am interested in taking part? 
If you would like to take part in the study then please read and sign the consent form also 
given to you and collect the questionnaire pack from the reception desk to complete. If you 
do not have the consent form or access to the questionnaire packs then please ask the 
individual who gave you this information sheet and they will be able to provide these for you. 
 
If you would like to discuss the study further then please contact: 
 
Zoe Mawby z.mawby@bath.ac.uk (Clinical Psychologist in Training at the University of 
Bath currently working in AWP CAMHS services in Weston-Super Mare. This piece of 
research will form part of my D. Clin. Psy qualification and is supervised by Dr Cara Davis- 
Clinical Psychologist/Clinical Tutor at the University of Bath)  
 
Thank you for taking the time to read this information sheet. Please do not hesitate to contact 
us if you would like further information. 
 
Links to Useful Information and Support  
 
• National Kidney Patients UK Helpline - http://www.kidney.org.uk/helpline 
Tel: 0845 601 02 09 
Email: Helpline@kidney.org.uk 
 
• National Kidney Patients Help and Info - http://www.kidney.org.uk/help-and-info/ 
 
• British Kidney Patient Assosication Counselling and Support Service-  
http://www.britishkidney-pa.co.uk/patient-support/counselling-and-support-service 
 Tel: 01420 541424 





















Thank you for taking part in this study 
Below is some information on the purpose of the study and what happens next 
 
What was the study interested in? 
You have taken part in a study which will help us to understand the different thought processes and 
emotional experiences that might occur in response to living with chronic health conditions. 
 
The questionnaires you completed were designed to capture your experience of living with your chronic 
health condition and your emotional and psychological reactions to this. 
 
In this study we are interested in something called Mental Defeat (MD). MD is a psychological state 
where you feel as though you have no control over your future and you feel as though you have lost 
your identity as an independent human being. Research has shown that when MD occurs in Chronic 
Pain patients these patients experience greater psychological distress and respond less well to treatment.   
 
We are collecting data from two groups of individuals; those with Inflammatory Arthritis and those 
with Chronic Kidney Disease (CKD). We are interested in seeing if there are differences in the ways 
thoughts and feelings work in relation to MD across different health conditions. It is hoped that by 
understanding more about the different thought and emotional processes that occur we can tailor support 
packages to specific health conditions so that the best help is being offered.  
 
What happens next? 
Responses to the questionnaires will be collated and analysed. The results of the study will be written 
up and submitted as part of the portfolio for the D. ClinPsy qualification and it is hoped that the study 
will also be published in a scientific journal.  
 
A summary of the results of the study will be made available to your medical clinic/posted in the waiting 
room in the coming months and online on the following website: (url tbc). 
 
We hope that you feel satisfied with the information you have been provided and are glad you took part. 
However, if you have any concerns or wish to complain about any aspect of the study, you should 
initially contact the project lead, Zoe Mawby (Clinical Psychologist in Training, contact details below) 
who will do her best to address your concerns. You can also contact North Bristol NHS Trust Advice 
and Complaints Team (ACT, details below).  
 
Once again, thank you for the time you spent completing the study.  
 
Contact Details: 
Zoe Mawby (Clinical Psychologist in Training at the University of Bath) z.mawby@bath.ac.uk 
Supervised by Dr Cara Davis (Clinical Psychologist/Clinical Tutor at the University of Bath), Professor 
Paul Salkovskis (Programme Director, University of Bath), Dr Suzanne Whitehead (Clinical Psychologist, 
Southmead Hospital) and Dr Kate Druett (Clinical Psychologist at Southmead Hospital)  
 
Advice and Complaints Team (ACT), Beaufort House, Beaufort Way, Southmead Hospital, Bristol, BS10 5NB. 

































The circulation of the Journal is worldwide. Papers are invited and encouraged from 
authors throughout the world. 
2. Length 
Papers describing quantitative research (including reviews with quantitative analyses) 
should be no more than 5000 words (excluding the abstract, reference list, tables and 
figures). Papers describing qualitative research (including reviews with qualitative 
analyses) should be no more than 6000 words (including quotes, whether in the text or 
in tables, but excluding the abstract, tables, figures and references). The Editors retain 
discretion to publish papers beyond this length in cases where the clear and concise 
expression of the scientific content requires greater length. 
3. Editorial policy 
The Journal receives a large volume of papers to review each year, and in order to make 
the process as efficient as possible for authors and editors alike, all papers are initially 
examined by the Editors to ascertain whether the article is suitable for full peer review. 
In order to qualify for full review, papers must meet the following criteria: 
• the content of the paper falls within the scope of the Journal 
• the methods and/or sample size are appropriate for the questions being addressed 
• research with student populations is appropriately justified 
• the word count is within the stated limit for the Journal (i.e. 5000 words, or 6,000 words 
for qualitative papers) 
4. Submission and reviewing 
All manuscripts must be submitted via Editorial Manager. The Journal operates a policy 





submissions that are out of scope or otherwise inappropriate will be rejected by the 
editors without external peer review to avoid unnecessary delays. Before submitting, 
please read the terms and conditions of submission and the declaration of competing 
interests. You may also like to use the Submission Checklist to help your prepare your 
paper. 
5. Manuscript requirements 
• Contributions must be typed in double spacing with wide margins. All sheets must be 
numbered. 
• Manuscripts should be preceded by a title page which includes a full list of authors and 
their affiliations, as well as the corresponding author's contact details. You may like to 
use this template. When entering the author names into Editorial Manager, the 
corresponding author will be asked to provide a CRediT contributor role to classify the 
role that each author played in creating the manuscript. Please see the Project 
CRediT website for a list of roles. 
• For articles containing original scientific research, a structured abstract of up to 250 
words should be included with the headings: Objectives, Design, Methods, Results, 
Conclusions. Review articles should use these headings: Purpose, Methods, Results, 
Conclusions. As the abstract is often the most widely visible part of your paper, it is 
important that it conveys succinctly all the most important features of your study. You 
can save words by writing short, direct sentences. Helpful hints about writing the 
conclusions to abstracts can be found here. 
• Statement of Contribution: All authors are required to provide a clear summary of ‘what 
is already known on this subject?’ and ‘what does this study add?’. Authors should 
identify existing research knowledge relating to the specific research question and give 
a summary of the new knowledge added by your study. Under each of these headings, 
please provide 2-3 (maximum) clear outcome statements (not process statements of what 
the paper does); the statements for 'what does this study add?' should be presented as 
bullet points of no more than 100 characters each. The Statement of Contribution should 





• Conflict of interest statement: We are now including a brief conflict of interest 
statement at the end of each accepted manuscript. You will be asked to provide 
information to generate this statement during the submission process. 
• The main document must be anonymous. Please do not mention the authors’ names or 
affiliations (including in the Method section) and always refer to any previous work in 
the third person. 
• Tables should be typed in double spacing, each on a separate page with a self-
explanatory title. Tables should be comprehensible without reference to the text. They 
should be placed at the end of the manuscript but they must be mentioned in the text. 
• Figures can be included at the end of the document or attached as separate files, 
carefully labelled in initial capital/lower case lettering with symbols in a form consistent 
with text use. Unnecessary background patterns, lines and shading should be avoided. 
Captions should be listed on a separate sheet. The resolution of digital images must be at 
least 300 dpi. All figures must be mentioned in the text. 
• For reference citations, please use APA style. Particular care should be taken to ensure 
that references are accurate and complete. Give all journal titles in full and provide doi 
numbers where possible for journal articles. For example: 
 
Author, A., Author, B., & Author, C. (1995). Title of book. City, Country: Publisher. 
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• SI units must be used for all measurements, rounded off to practical values if 
appropriate, with the imperial equivalent in parentheses. 
• In normal circumstances, effect size should be incorporated. 
• Authors are requested to avoid the use of sexist language. 
• Authors are responsible for acquiring written permission to publish lengthy quotations, 
illustrations, etc. for which they do not own copyright. For guidelines on editorial style, 






• Manuscripts describing clinical trials are encouraged to submit in accordance with 
the CONSORT statement on reporting randomised controlled trials. 
• Manuscripts reporting systematic reviews and meta-analyses are encouraged to submit 
in accordance with the PRISMA statement. 
• Manuscripts reporting interventions are encouraged to describe them in accordance 
with the TIDieR checklist. 
 
 
 
